Crossreactive	O
recognition	O
of	O
viral	O
,	O
self	O
,	O
and	O
bacterial	O
peptide	O
ligands	O
by	O
human	B-cell_type
class	I-cell_type
I-restricted	I-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocyte	I-cell_type
clonotypes	I-cell_type
:	I-cell_type
implications	O
for	O
molecular	O
mimicry	O
in	O
autoimmune	O
disease	O
.	O

The	O
immunodominant	O
,	O
CD8	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cytotoxic	I-cell_type
T	I-cell_type
lymphocyte	I-cell_type
(	O
CTL	O
)	O
response	O
to	O
the	O
HLA-B8-restricted	O
peptide	O
,	O
RAKFKQLL	O
,	O
located	O
in	O
the	O
Epstein-Barr	B-protein
virus	I-protein
immediate-early	I-protein
antigen	I-protein
,	O
BZLF1	B-protein
,	O
is	O
characterized	O
by	O
a	O
diverse	O
T	B-protein
cell	I-protein
receptor	I-protein
(	I-protein
TCR	I-protein
)	I-protein
repertoire	I-protein
.	O

Here	O
,	O
we	O
show	O
that	O
this	O
diversity	O
can	O
be	O
partitioned	O
on	O
the	O
basis	O
of	O
crossreactive	O
cytotoxicity	O
patterns	O
involving	O
the	O
recognition	O
of	O
a	O
self	O
peptide-RSKFRQIV-located	O
in	O
a	O
serine/threonine	B-protein
kinase	I-protein
and	O
a	O
bacterial	O
peptide-RRKYKQII-located	O
in	O
Staphylococcus	B-protein
aureus	I-protein
replication	I-protein
initiation	I-protein
protein	I-protein
.	O

Thus	O
CTL	B-cell_line
clones	I-cell_line
that	O
recognized	O
the	O
viral	O
,	O
self	O
,	O
and	O
bacterial	O
peptides	O
expressed	O
a	O
highly	O
restricted	O
alphabeta	O
TCR	B-protein
phenotype	O
.	O

The	O
CTL	B-cell_line
clones	I-cell_line
that	O
recognized	O
viral	O
and	O
self	O
peptides	O
were	O
more	O
oligoclonal	O
,	O
whereas	O
clones	O
that	O
strictly	O
recognized	O
the	O
viral	O
peptide	O
displayed	O
a	O
diverse	O
TCR	B-protein
profile	O
.	O

Interestingly	O
,	O
the	O
self	O
and	O
bacterial	O
peptides	O
equally	O
were	O
substantially	O
less	O
effective	O
than	O
the	O
cognate	O
viral	O
peptide	O
in	O
sensitizing	O
target	O
cell	O
lysis	O
,	O
and	O
also	O
resulted	O
only	O
in	O
a	O
weak	O
reactivation	O
of	O
memory	B-cell_type
CTLs	I-cell_type
in	O
limiting	O
dilution	O
assays	O
,	O
whereas	O
the	O
cognate	O
peptide	O
was	O
highly	O
immunogenic	O
.	O

The	O
described	O
crossreactions	O
show	O
that	O
human	O
antiviral	O
,	O
CD8	O
(	O
+	O
)	O
CTL	O
responses	O
can	O
be	O
shaped	O
by	O
peptide	O
ligands	O
derived	O
from	O
autoantigens	O
and	O
environmental	O
bacterial	O
antigens	O
,	O
thereby	O
providing	O
a	O
firm	O
structural	O
basis	O
for	O
molecular	O
mimicry	O
involving	O
class	O
I-restricted	B-cell_line
CTLs	I-cell_line
in	O
the	O
pathogenesis	O
of	O
autoimmune	O
disease	O
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

96	NULL
,	NULL
pp	NULL
.	NULL

2279-2284	NULL
,	NULL
March	NULL
1999	NULL
Immunology	NULL
Crossreactive	NULL
recognition	NULL
of	NULL
viral	NULL
,	NULL
self	NULL
,	NULL
and	NULL
bacterial	NULL
peptide	NULL
ligands	NULL
by	NULL
human	NULL
class	NULL
II-restricted	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
clonotypes	NULL
:	NULL
Implications	NULL
for	NULL
molecular	NULL
mimicry	NULL
in	NULL
autoimmune	NULL
disease	NULL
IHnor	NULL
S.	NULL
MiskoTt	NULL
,	NULL
SImonE	NULL
M.	NULL
CROSS	NULL
,	NULL
RAJIV	NULL
KHANNA	NULL
,	NULL
SUZANNE	NULL
L.	NULL
ELLIOTT	NULL
,	NULL
CHRISTOPHER	NULL
SCHMIDT	NULL
,	NULL
STEPHANIE	NULL
J.	NULL
PYE	NULL
,	NULL
AND	NULL
SHARON	NULL
L.	NULL
SILINS	NULL
Epstein-Barr	NULL
Virus	NULL
Unit	NULL
,	NULL
Queensland	NULL
Institute	NULL
of	NULL
Medical	NULL
Research	NULL
and	NULL
Joint	NULL
Experimental	NULL
Oncology	NULL
,	NULL
University	NULL
of	NULL
Queensland	NULL
,	NULL
Brisbane	NULL
,	NULL
4029	NULL
,	NULL
Australia	NULL
Edited	NULL
by	NULL
Jack	NULL
Leonard	NULL
Strominger	NULL
,	NULL
Harvard	NULL
University	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
,	NULL
and	NULL
approved	NULL
November	NULL
24	NULL
,	NULL
1998	NULL
(	NULL
received	NULL
for	NULL
review	NULL
October	NULL
26	NULL
,	NULL
1998	NULL
)	NULL
ABSTRACT	NULL
The	NULL
immunodominant	NULL
,	NULL
CD8*	NULL
cytotoxic	NULL
T	NULL
lymphocyte	NULL
(	NULL
CTL	NULL
)	NULL
response	NULL
to	NULL
the	NULL
HLA-B8-restricted	NULL
peptide	NULL
,	NULL
RAK-FKQLL	NULL
,	NULL
located	NULL
in	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
immediate-early	NULL
antigen	NULL
,	NULL
BZLF1	NULL
,	NULL
is	NULL
characterized	NULL
by	NULL
a	NULL
diverse	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
repertoire	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
show	NULL
that	NULL
this	NULL
diversity	NULL
can	NULL
be	NULL
partitioned	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
crossreactive	NULL
cytotoxicity	NULL
patterns	NULL
involving	NULL
the	NULL
recognition	NULL
of	NULL
a	NULL
self	NULL
peptide-RSKFRQIV-located	NULL
in	NULL
a	NULL
serine/threonine	NULL
kinase	NULL
and	NULL
a	NULL
bacterial	NULL
peptide-RRKYKQII-located	NULL
in	NULL
Staphylococcus	NULL
aureus	NULL
replication	NULL
initiation	NULL
protein	NULL
.	NULL

Thus	NULL
CTL	NULL
clones	NULL
that	NULL
recognized	NULL
the	NULL
viral	NULL
,	NULL
self	NULL
,	NULL
and	NULL
bacterial	NULL
peptides	NULL
expressed	NULL
a	NULL
highly	NULL
restricted	NULL
«	NULL
B	NULL
TCR	NULL
phenotype	NULL
.	NULL

The	NULL
CTL	NULL
clones	NULL
that	NULL
recognized	NULL
viral	NULL
and	NULL
self	NULL
peptides	NULL
were	NULL
more	NULL
oligoclonal	NULL
,	NULL
whereas	NULL
clones	NULL
that	NULL
strictly	NULL
recognized	NULL
the	NULL
viral	NULL
peptide	NULL
displayed	NULL
a	NULL
diverse	NULL
TCR	NULL
profile	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
self	NULL
and	NULL
bacterial	NULL
peptides	NULL
equally	NULL
were	NULL
substantially	NULL
less	NULL
effective	NULL
than	NULL
the	NULL
cognate	NULL
viral	NULL
peptide	NULL
in	NULL
sensitizing	NULL
target	NULL
cell	NULL
lysis	NULL
,	NULL
and	NULL
also	NULL
resulted	NULL
only	NULL
in	NULL
a	NULL
weak	NULL
reactivation	NULL
of	NULL
memory	NULL
CTLs	NULL
in	NULL
limiting	NULL
dilution	NULL
assays	NULL
,	NULL
whereas	NULL
the	NULL
cognate	NULL
peptide	NULL
was	NULL
highly	NULL
immunogenic	NULL
.	NULL

The	NULL
described	NULL
crossreactions	NULL
show	NULL
that	NULL
human	NULL
antiviral	NULL
,	NULL
CD8+*	NULL
CTL	NULL
responses	NULL
can	NULL
be	NULL
shaped	NULL
by	NULL
peptide	NULL
ligands	NULL
derived	NULL
from	NULL
autoantigens	NULL
and	NULL
environmental	NULL
bacterial	NULL
antigens	NULL
,	NULL
thereby	NULL
providing	NULL
a	NULL
firm	NULL
structural	NULL
basis	NULL
for	NULL
molecular	NULL
mimicry	NULL
involving	NULL
class	NULL
I-restricted	NULL
CTLs	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
autoimmune	NULL
disease	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
,	NULL
a	NULL
human	NULL
gamma	NULL
herpesvirus	NULL
,	NULL
achieves	NULL
its	NULL
ubiquitous	NULL
distribution	NULL
by	NULL
a	NULL
dual	NULL
strategy	NULL
of	NULL
latency	NULL
to	NULL
guarantee	NULL
life-long	NULL
persistence	NULL
and	NULL
intermittent	NULL
replication	NULL
to	NULL
ensure	NULL
transmission	NULL
.	NULL

The	NULL
probable	NULL
site	NULL
of	NULL
viral	NULL
latency	NULL
is	NULL
a	NULL
reservoir	NULL
of	NULL
circulating	NULL
B	NULL
cells	NULL
,	NULL
whereas	NULL
the	NULL
source	NULL
of	NULL
infectious	NULL
virus	NULL
in	NULL
the	NULL
oropharynx	NULL
is	NULL
most	NULL
likely	NULL
reliant	NULL
on	NULL
an	NULL
episodic	NULL
supply	NULL
of	NULL
virus	NULL
from	NULL
permissively	NULL
infected	NULL
B	NULL
cells	NULL
infiltrating	NULL
the	NULL
mucosal	NULL
epithelium	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Different	NULL
forms	NULL
of	NULL
viral	NULL
latency	NULL
can	NULL
be	NULL
distinguished	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
particular	NULL
patterns	NULL
of	NULL
virus	NULL
latent	NULL
gene	NULL
expression	NULL
(	NULL
3	NULL
)	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
EBV	NULL
can	NULL
infect	NULL
and	NULL
transform	NULL
B	NULL
cells	NULL
to	NULL
grow	NULL
continuously	NULL
in	NULL
vitro	NULL
as	NULL
lymphoblastoid	NULL
cell	NULL
lines	NULL
(	NULL
LCLs	NULL
)	NULL
that	NULL
express	NULL
the	NULL
full	NULL
array	NULL
of	NULL
the	NULL
immunogenic	NULL
latency	NULL
proteins	NULL
including	NULL
EBV	NULL
nuclear	NULL
antigens	NULL
1-6	NULL
and	NULL
latent	NULL
membrane	NULL
proteins	NULL
1	NULL
and	NULL
2	NULL
.	NULL

Transformed	NULL
B	NULL
cells	NULL
with	NULL
similar	NULL
viral	NULL
antigen	NULL
expression	NULL
represent	NULL
EBV-associated	NULL
polyclonal	NULL
lymphomas	NULL
in	NULL
immunocompromised	NULL
individuals	NULL
(	NULL
4	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
it	NULL
is	NULL
thought	NULL
that	NULL
EBV	NULL
persists	NULL
latently	NULL
in	NULL
vivo	NULL
in	NULL
resting	NULL
B	NULL
cells	NULL
that	NULL
only	NULL
express	NULL
latent	NULL
membrane	NULL
protein	NULL
2A	NULL
and	NULL
remain	NULL
immunologically	NULL
silent	NULL
through	NULL
lack	NULL
of	NULL
expression	NULL
of	NULL
the	NULL
costimulatory	NULL
molecule	NULL
B7	NULL
(	NULL
5	NULL
)	NULL
.	NULL

The	NULL
successful	NULL
coexistence	NULL
with	NULL
its	NULL
host	NULL
of	NULL
the	NULL
most	NULL
potent	NULL
transforming	NULL
virus	NULL
known	NULL
is	NULL
considered	NULL
to	NULL
be	NULL
due	NULL
to	NULL
immu-	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

PNAS	NULL
is	NULL
available	NULL
online	NULL
at	NULL
www.pnas.org	NULL
.	NULL

2279	NULL
nosurveillance	NULL
by	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
(	NULL
CTLs	NULL
)	NULL
in	NULL
controlling	NULL
the	NULL
outgrowth	NULL
of	NULL
virus	NULL
transformed	NULL
B	NULL
cells	NULL
,	NULL
and	NULL
limiting	NULL
viral	NULL
replication	NULL
,	NULL
but	NULL
without	NULL
unduly	NULL
compromising	NULL
viral	NULL
transmission	NULL
(	NULL
reviewed	NULL
in	NULL
ref	NULL
.	NULL

6	NULL
)	NULL
.	NULL

A	NULL
primary	NULL
infection	NULL
with	NULL
EBV	NULL
can	NULL
result	NULL
in	NULL
the	NULL
self-limiting	NULL
,	NULL
lymphoproliferative	NULL
disease	NULL
acute	NULL
infectious	NULL
mononucleosis	NULL
.	NULL

A	NULL
substantial	NULL
proportion	NULL
of	NULL
the	NULL
in	NULL
vivo	NULL
activated	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
recognize	NULL
peptide	NULL
epitopes	NULL
in	NULL
viral	NULL
proteins	NULL
associated	NULL
with	NULL
latency	NULL
and	NULL
replication	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
,	NULL
and	NULL
there	NULL
is	NULL
now	NULL
compelling	NULL
evidence	NULL
that	NULL
imprinting	NULL
of	NULL
the	NULL
memory	NULL
T	NULL
cell	NULL
repertoire	NULL
can	NULL
occur	NULL
during	NULL
primary	NULL
viral	NULL
or	NULL
bacterial	NULL
infection	NULL
and	NULL
remain	NULL
stable	NULL
over	NULL
time	NULL
(	NULL
8-11	NULL
)	NULL
.	NULL

Diversity	NULL
within	NULL
the	NULL
T	NULL
cell	NULL
repertoire	NULL
can	NULL
be	NULL
estimated	NULL
by	NULL
analyzing	NULL
the	NULL
distribution	NULL
of	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
rearrange-ments	NULL
.	NULL

The	NULL
clonally	NULL
distributed	NULL
«	NULL
B	NULL
TCR	NULL
heterodimer	NULL
that	NULL
interacts	NULL
with	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
-peptide	NULL
complex	NULL
presented	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
target	NULL
cells	NULL
is	NULL
generated	NULL
through	NULL
somatic	NULL
recombination	NULL
of	NULL
variable	NULL
(	NULL
V	NULL
;	NULL
TCRAV	NULL
and	NULL
TCRVB	NULL
)	NULL
,	NULL
diversity	NULL
(	NULL
D	NULL
;	NULL
TCRBD	NULL
)	NULL
,	NULL
and	NULL
joining	NULL
(	NULL
J	NULL
;	NULL
TCRAJ	NULL
and	NULL
TCRBJ	NULL
)	NULL
gene	NULL
segments	NULL
during	NULL
T	NULL
cell	NULL
ontogeny	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Additional	NULL
repertoire	NULL
diversity	NULL
is	NULL
created	NULL
by	NULL
the	NULL
imprecise	NULL
joining	NULL
of	NULL
the	NULL
different	NULL
gene	NULL
segments	NULL
and	NULL
the	NULL
quasirandom	NULL
insertion	NULL
or	NULL
deletion	NULL
of	NULL
nucleotides	NULL
at	NULL
the	NULL
V-	NULL
(	NULL
D	NULL
)	NULL
-J	NULL
junctional	NULL
regions	NULL
that	NULL
span	NULL
the	NULL
complementarity	NULL
determining	NULL
region	NULL
3	NULL
(	NULL
CDR3	NULL
)	NULL
,	NULL
a	NULL
region	NULL
of	NULL
high	NULL
variability	NULL
in	NULL
length	NULL
and	NULL
codon	NULL
usage	NULL
that	NULL
makes	NULL
direct	NULL
contact	NULL
with	NULL
self	NULL
and	NULL
foreign	NULL
peptide	NULL
ligands	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

The	NULL
majority	NULL
of	NULL
CTL	NULL
epitopes	NULL
that	NULL
have	NULL
been	NULL
mapped	NULL
to	NULL
the	NULL
latent	NULL
EBV	NULL
nuclear	NULL
antigen	NULL
and	NULL
latent	NULL
membrane	NULL
proteins	NULL
,	NULL
and	NULL
immediate	NULL
early	NULL
and	NULL
early	NULL
lytic	NULL
cycle	NULL
proteins	NULL
,	NULL
in	NULL
primary	NULL
and	NULL
persistent	NULL
infection	NULL
,	NULL
are	NULL
recognized	NULL
by	NULL
CD8	NULL
,	NULL
class	NULL
T-restricted	NULL
CTLs	NULL
(	NULL
6	NULL
)	NULL
,	NULL
and	NULL
clonal	NULL
expansions	NULL
in	NULL
response	NULL
to	NULL
individual	NULL
epitopes	NULL
have	NULL
involved	NULL
the	NULL
selection	NULL
of	NULL
highly	NULL
restricted	NULL
or	NULL
diverse	NULL
TCR	NULL
repertoires	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
a	NULL
single	NULL
TCR	NULL
can	NULL
interact	NULL
with	NULL
multiple	NULL
peptide	NULL
ligands	NULL
that	NULL
share	NULL
,	NULL
for	NULL
instance	NULL
,	NULL
a	NULL
specific	NULL
motif	NULL
,	NULL
limited	NULL
linear	NULL
sequence	NULL
homology	NULL
or	NULL
no	NULL
obvious	NULL
structural	NULL
homology	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

This	NULL
aptitude	NULL
for	NULL
crossreactive	NULL
recognition	NULL
forms	NULL
in	NULL
essence	NULL
the	NULL
basis	NULL
of	NULL
the	NULL
molecular	NULL
mimicry	NULL
hypothesis	NULL
in	NULL
which	NULL
it	NULL
is	NULL
proposed	NULL
that	NULL
the	NULL
sharing	NULL
,	NULL
in	NULL
structure	NULL
or	NULL
sequence	NULL
,	NULL
of	NULL
peptides	NULL
between	NULL
microbes	NULL
and	NULL
host	NULL
proteins	NULL
can	NULL
trigger	NULL
the	NULL
activation	NULL
of	NULL
antimicrobial	NULL
,	NULL
antiself	NULL
T	NULL
cells	NULL
that	NULL
can	NULL
initiate	NULL
and/or	NULL
This	NULL
paper	NULL
was	NULL
submitted	NULL
directly	NULL
(	NULL
Track	NULL
II	NULL
)	NULL
to	NULL
the	NULL
Proceedings	NULL
office	NULL
.	NULL

Abbreviations	NULL
:	NULL
EBV	NULL
,	NULL
Epstein-Barr	NULL
virus	NULL
;	NULL
CTL	NULL
,	NULL
cytotoxic	NULL
T	NULL
lympho-cyte	NULL
;	NULL
LCL	NULL
,	NULL
lymphoblastoid	NULL
cell	NULL
line	NULL
;	NULL
TCR	NULL
,	NULL
T	NULL
cell	NULL
receptor	NULL
;	NULL
BZLF1	NULL
,	NULL
EBV	NULL
immediate-early	NULL
antigen	NULL
;	NULL
PBMC	NULL
,	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cell	NULL
;	NULL
RAK	NULL
,	NULL
RAKFQLL	NULL
(	NULL
residues	NULL
190-197	NULL
)	NULL
;	NULL
RSK	NULL
,	NULL
RSKFRQIV	NULL
(	NULL
residues	NULL
156-163	NULL
)	NULL
;	NULL
RRK	NULL
,	NULL
RRKYKQII	NULL
(	NULL
residues	NULL
269-276	NULL
)	NULL
;	NULL
V-	NULL
(	NULL
D	NULL
)	NULL
-J	NULL
,	NULL
variable-diversity-joining	NULL
;	NULL
CDR3	NULL
,	NULL
compatibility	NULL
determining	NULL
region	NULL
3	NULL
;	NULL
MHC	NULL
,	NULL
major	NULL
histocompatibility	NULL
complex	NULL
;	NULL
PHA	NULL
,	NULL
phytohemagglutinin	NULL
.	NULL

Data	NULL
deposition	NULL
:	NULL
The	NULL
sequences	NULL
reported	NULL
in	NULL
this	NULL
paper	NULL
have	NULL
been	NULL
deposited	NULL
in	NULL
the	NULL
GenBank	NULL
database	NULL
(	NULL
accession	NULL
nos	NULL
.	NULL

AJ235202-AJ235225	NULL
)	NULL
.	NULL

tTo	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

e-mail	NULL
:	NULL
ihorM	NULL
@	NULL
gimr.edu.au	NULL
.	NULL

2280	NULL
Immunology	NULL
:	NULL
Misko	NULL
et	NULL
al	NULL
.	NULL

perpetuate	NULL
autoimmune	NULL
disease	NULL
(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
autoreactivity	NULL
could	NULL
be	NULL
induced	NULL
as	NULL
an	NULL
outcome	NULL
of	NULL
bystander	NULL
activation	NULL
of	NULL
antiself	NULL
T	NULL
cells	NULL
during	NULL
an	NULL
inflammatory	NULL
response	NULL
to	NULL
a	NULL
microbial	NULL
infection	NULL
(	NULL
21	NULL
)	NULL
.	NULL

There	NULL
is	NULL
no	NULL
longer	NULL
a	NULL
difficulty	NULL
in	NULL
explaining	NULL
the	NULL
presence	NULL
of	NULL
potentially	NULL
autoreactive	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
periphery	NULL
as	NULL
they	NULL
appear	NULL
to	NULL
be	NULL
a	NULL
normal	NULL
consequence	NULL
of	NULL
positive	NULL
selection	NULL
in	NULL
the	NULL
thymus	NULL
and	NULL
are	NULL
kept	NULL
in	NULL
control	NULL
by	NULL
peripheral	NULL
tolerance	NULL
(	NULL
22-24	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
breaking	NULL
of	NULL
tolerance	NULL
in	NULL
bystander	NULL
activation	NULL
could	NULL
occur	NULL
as	NULL
an	NULL
outcome	NULL
of	NULL
an	NULL
abundant	NULL
release	NULL
of	NULL
cytokines	NULL
/autoantigens	NULL
during	NULL
inflammation	NULL
and	NULL
tissue	NULL
damage	NULL
,	NULL
and	NULL
in	NULL
molecular	NULL
mimicry	NULL
by	NULL
an	NULL
increased	NULL
propensity	NULL
of	NULL
activated	NULL
antimicrobial	NULL
T	NULL
cells	NULL
to	NULL
respond	NULL
to	NULL
low	NULL
affinity	NULL
self	NULL
peptide	NULL
mimics	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

It	NULL
is	NULL
likely	NULL
that	NULL
EBV-infected	NULL
B	NULL
cells	NULL
are	NULL
a	NULL
continual	NULL
source	NULL
of	NULL
replicating	NULL
virus	NULL
throughout	NULL
life-long	NULL
infection	NULL
(	NULL
1	NULL
)	NULL
.	NULL

The	NULL
pivotal	NULL
switch	NULL
from	NULL
latency	NULL
to	NULL
virus	NULL
replication	NULL
in	NULL
B	NULL
cells	NULL
involves	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
immediate-early	NULL
BZLFI	NULL
gene	NULL
(	NULL
27	NULL
)	NULL
,	NULL
and	NULL
Epstein-Barr	NULL
virus	NULL
immediate-early	NULL
antigen	NULL
,	NULL
BZLF1	NULL
(	NULL
also	NULL
termed	NULL
ZEBRA	NULL
or	NULL
Zta	NULL
)	NULL
protein	NULL
has	NULL
been	NULL
detected	NULL
in	NULL
productively	NULL
infected	NULL
B	NULL
cells	NULL
during	NULL
primary	NULL
infection	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Of	NULL
interest	NULL
,	NULL
B	NULL
cells	NULL
from	NULL
healthy	NULL
virus	NULL
carriers	NULL
expressed	NULL
BZLF1	NULL
transcripts	NULL
,	NULL
but	NULL
not	NULL
BZLF1	NULL
protein	NULL
,	NULL
suggesting	NULL
that	NULL
cells	NULL
undergoing	NULL
the	NULL
carly	NULL
stages	NULL
of	NULL
viral	NULL
replication	NULL
might	NULL
be	NULL
continually	NULL
eliminated	NULL
by	NULL
BZLF1-specific	NULL
CTLs	NULL
.	NULL

Certainly	NULL
the	NULL
high	NULL
CTL	NULL
precursor	NULL
frequencies	NULL
to	NULL
the	NULL
BZLFl-encoded	NULL
epitope	NULL
,	NULL
RAKFKQLL	NULL
(	NULL
residues	NULL
190-197	NULL
;	NULL
referred	NULL
to	NULL
as	NULL
RAK	NULL
hereafter	NULL
)	NULL
(	NULL
29	NULL
)	NULL
that	NULL
are	NULL
maintained	NULL
in	NULL
the	NULL
peripheral	NULL
blood	NULL
of	NULL
healthy	NULL
,	NULL
HLA-B8*	NULL
virus	NULL
carriers	NULL
could	NULL
be	NULL
an	NULL
outcome	NULL
of	NULL
repeated	NULL
antigen	NULL
exposure	NULL
(	NULL
7	NULL
,	NULL
30	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
selection	NULL
of	NULL
diverse	NULL
RAK	NULL
-reactive	NULL
clonotypes	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
abundant	NULL
antigen	NULL
presentation	NULL
,	NULL
may	NULL
indicate	NULL
a	NULL
low	NULL
affinity	NULL
TCR	NULL
response	NULL
that	NULL
is	NULL
sensitive	NULL
to	NULL
crossreactions	NULL
with	NULL
multiple	NULL
peptide	NULL
ligands	NULL
.	NULL

To	NULL
investigate	NULL
this	NULL
possibility	NULL
,	NULL
we	NULL
initiated	NULL
a	NULL
study	NULL
in	NULL
which	NULL
RAK-reactive	NULL
CTL	NULL
clones	NULL
were	NULL
used	NULL
as	NULL
effectors	NULL
against	NULL
target	NULL
cells	NULL
displaying	NULL
peptide	NULL
homologues	NULL
derived	NULL
from	NULL
known	NULL
human	NULL
pathogens	NULL
or	NULL
putative	NULL
autoantigens	NULL
.	NULL

Such	NULL
potentially	NULL
crossreactive	NULL
homologues	NULL
were	NULL
identified	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
a	NULL
combination	NULL
of	NULL
their	NULL
primary	NULL
sequence	NULL
similarities	NULL
with	NULL
the	NULL
peptide	NULL
,	NULL
RAK	NULL
,	NULL
and	NULL
the	NULL
peptide	NULL
binding	NULL
motif	NULL
for	NULL
the	NULL
restricting	NULL
HLA-B8	NULL
allele	NULL
(	NULL
31	NULL
)	NULL
by	NULL
searching	NULL
the	NULL
SwissProt	NULL
database	NULL
.	NULL

Similar	NULL
principles	NULL
have	NULL
been	NULL
used	NULL
successfully	NULL
to	NULL
identify	NULL
peptide	NULL
mimics	NULL
in	NULL
microbial	NULL
antigens	NULL
or	NULL
autoantigens	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
structural	NULL
similarity	NULL
or	NULL
linear	NULL
sequence	NULL
homology	NULL
(	NULL
20	NULL
,	NULL
32	NULL
)	NULL
.	NULL

While	NULL
there	NULL
has	NULL
been	NULL
a	NULL
general	NULL
tendency	NULL
to	NULL
implicate	NULL
MHC	NULL
class	NULL
II-restricted	NULL
crossreactive	NULL
peptides	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
autoreactive	NULL
T	NULL
cells	NULL
(	NULL
33	NULL
)	NULL
,	NULL
there	NULL
are	NULL
no	NULL
a	NULL
priori	NULL
reasons	NULL
for	NULL
excluding	NULL
a	NULL
possible	NULL
involvement	NULL
of	NULL
class	NULL
I-restricted	NULL
peptides	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
autoimmune	NULL
disease	NULL
.	NULL

We	NULL
show	NULL
herein	NULL
that	NULL
individual	NULL
MHC	NULL
class	NULL
I-restricted	NULL
CTL	NULL
clones	NULL
can	NULL
recognize	NULL
peptide	NULL
ligands	NULL
,	NULL
sharing	NULL
linear	NULL
peptide	NULL
homology	NULL
,	NULL
from	NULL
viral	NULL
,	NULL
bacterial	NULL
,	NULL
and	NULL
self	NULL
proteins	NULL
.	NULL

Moreover	NULL
,	NULL
multiple	NULL
clones	NULL
that	NULL
were	NULL
involved	NULL
in	NULL
this	NULL
``	NULL
three-way	NULL
``	NULL
molecular	NULL
mimicry	NULL
expressed	NULL
a	NULL
dominant	NULL
«	NULL
B	NULL
TCR	NULL
phenotype	NULL
.	NULL

These	NULL
findings	NULL
raise	NULL
interesting	NULL
issues	NULL
about	NULL
the	NULL
possible	NULL
role	NULL
of	NULL
CD8*	NULL
T	NULL
cells	NULL
in	NULL
autoimmune	NULL
disease	NULL
,	NULL
and	NULL
the	NULL
significance	NULL
of	NULL
self	NULL
and	NULL
microbial	NULL
peptide	NULL
ligands	NULL
in	NULL
shaping	NULL
the	NULL
peripheral	NULL
T	NULL
cell	NULL
repertoire	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
Donors	NULL
and	NULL
Cell	NULL
Lines	NULL
.	NULL

Blood	NULL
samples	NULL
were	NULL
taken	NULL
from	NULL
three	NULL
healthy	NULL
HLA-B8*	NULL
long-term	NULL
virus	NULL
carriers	NULL
,	NULL
SP	NULL
,	NULL
LC	NULL
,	NULL
and	NULL
MM	NULL
.	NULL

Autologous	NULL
LCLs	NULL
were	NULL
established	NULL
from	NULL
donor	NULL
SP	NULL
and	NULL
an	NULL
HLA-A1/B8	NULL
homozygous	NULL
donor	NULL
BM	NULL
by	NULL
transformation	NULL
of	NULL
B	NULL
cells	NULL
with	NULL
exogenous	NULL
type	NULL
A	NULL
EBV	NULL
(	NULL
QIMR-WIL	NULL
isolate	NULL
)	NULL
.	NULL

LCLs	NULL
were	NULL
routinely	NULL
maintained	NULL
in	NULL
growth	NULL
medium	NULL
consisting	NULL
of	NULL
RPMI	NULL
1640	NULL
medium	NULL
,	NULL
2	NULL
mM	NULL
glutamine	NULL
,	NULL
100	NULL
units/ml	NULL
penicillin	NULL
,	NULL
100	NULL
ug/ml	NULL
streptomycin	NULL
,	NULL
and	NULL
10	NULL
%	NULL
(	NULL
vol/vol	NULL
)	NULL
heat-inactivated	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

Phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
blasts	NULL
were	NULL
generated	NULL
from	NULL
donors	NULL
SP	NULL
,	NULL
LC	NULL
,	NULL
MM	NULL
,	NULL
and	NULL
BM	NULL
as	NULL
described	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
Selection	NULL
and	NULL
Synthesis	NULL
of	NULL
Peptides	NULL
.	NULL

Peptide	NULL
homologues	NULL
were	NULL
identified	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
a	NULL
combination	NULL
of	NULL
their	NULL
primary	NULL
sequence	NULL
similarities	NULL
with	NULL
the	NULL
BZLF1-derived	NULL
peptide	NULL
,	NULL
RAK	NULL
,	NULL
and	NULL
the	NULL
peptide	NULL
binding	NULL
motif	NULL
for	NULL
HLA-B8	NULL
by	NULL
searching	NULL
the	NULL
SwissProt	NULL
database	NULL
using	NULL
the	NULL
motif	NULL
,	NULL
X-X-	NULL
[	NULL
KR	NULL
]	NULL
-	NULL
[	NULL
FY	NULL
]	NULL
-	NULL
[	NULL
KR	NULL
]	NULL
-	NULL
[	NULL
QON	NULL
]	NULL
-	NULL
[	NULL
LIVMJ	NULL
]	NULL
-	NULL
[	NULL
LIVM	NULL
]	NULL
;	NULL
amino	NULL
acid	NULL
sequence	NULL
is	NULL
denoted	NULL
in	NULL
standard	NULL
single	NULL
letter	NULL
code	NULL
,	NULL
where	NULL
X	NULL
represents	NULL
any	NULL
amino	NULL
acid	NULL
.	NULL

Seven	NULL
peptide	NULL
homologues	NULL
used	NULL
in	NULL
the	NULL
present	NULL
study	NULL
were	NULL
selected	NULL
from	NULL
a	NULL
vast	NULL
pool	NULL
of	NULL
identified	NULL
sequences	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
whether	NULL
they	NULL
were	NULL
derived	NULL
from	NULL
known	NULL
human	NULL
pathogens	NULL
or	NULL
putative	NULL
autoantigens	NULL
.	NULL

All	NULL
selected	NULL
peptides	NULL
were	NULL
purchased	NULL
from	NULL
Chiron	NULL
Technologies	NULL
(	NULL
Melbourne	NULL
,	NULL
Australia	NULL
)	NULL
.	NULL

Agar	NULL
Cloning	NULL
of	NULL
T	NULL
Cells	NULL
.	NULL

Peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMCs	NULL
)	NULL
from	NULL
donor	NULL
SP	NULL
were	NULL
activated	NULL
by	NULL
stimulation	NULL
with	NULL
the	NULL
y-irradiated	NULL
(	NULL
80	NULL
Gy	NULL
)	NULL
autologous	NULL
LCL	NULL
or	NULL
an	NULL
LCL	NULL
from	NULL
the	NULL
HLA-A1/B8	NULL
homozygous	NULL
individual	NULL
BM	NULL
at	NULL
a	NULL
stimulator/	NULL
responder	NULL
cell	NULL
ratio	NULL
of	NULL
1:20	NULL
,	NULL
and	NULL
T	NULL
cell	NULL
clones	NULL
were	NULL
generated	NULL
as	NULL
described	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Clones	NULL
were	NULL
maintained	NULL
in	NULL
growth	NULL
medium	NULL
containing	NULL
recombinant	NULL
interleukin	NULL
2	NULL
(	NULL
Chiron	NULL
Technologies	NULL
)	NULL
and	NULL
were	NULL
routinely	NULL
immunophenotyped	NULL
for	NULL
CD3	NULL
,	NULL
CD4	NULL
,	NULL
and	NULL
CD8	NULL
markers	NULL
as	NULL
described	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Cytotoxicity	NULL
Assay	NULL
.	NULL

CD8*	NULL
RAK-reactive	NULL
CTL	NULL
clones	NULL
from	NULL
donor	NULL
SP	NULL
were	NULL
used	NULL
as	NULL
effectors	NULL
against	NULL
PHA	NULL
blasts	NULL
pulsed	NULL
with	NULL
the	NULL
appropriate	NULL
peptide	NULL
(	NULL
100	NULL
ug/ml	NULL
,	NULL
0.2	NULL
ml	NULL
)	NULL
.	NULL

Target	NULL
cells	NULL
,	NULL
with	NULL
or	NULL
without	NULL
peptide	NULL
,	NULL
were	NULL
incubated	NULL
with	NULL
100	NULL
Ci	NULL
(	NULL
1	NULL
Ci	NULL
=	NULL
37	NULL
GBq	NULL
)	NULL
of	NULL
at	NULL
37°C	NULL
for	NULL
90	NULL
min	NULL
,	NULL
washed	NULL
twice	NULL
by	NULL
centrif-ugation	NULL
,	NULL
and	NULL
used	NULL
in	NULL
standard	NULL
4-h	NULL
'Cr-release	NULL
assays	NULL
.	NULL

Limiting	NULL
Dilution	NULL
Analysis	NULL
.	NULL

The	NULL
memory	NULL
CTL	NULL
precursor	NULL
frequencies	NULL
to	NULL
the	NULL
peptides	NULL
,	NULL
RAK	NULL
,	NULL
RSKFRQIV	NULL
(	NULL
residues	NULL
156-163	NULL
;	NULL
referred	NULL
to	NULL
as	NULL
RSK	NULL
hereafter	NULL
)	NULL
,	NULL
and	NULL
RRKYKQII	NULL
(	NULL
residues	NULL
269-276	NULL
;	NULL
referred	NULL
to	NULL
as	NULL
RRK	NULL
hereafter	NULL
)	NULL
,	NULL
were	NULL
quantified	NULL
by	NULL
using	NULL
limiting	NULL
dilution	NULL
analysis	NULL
as	NULL
described	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Amplification	NULL
and	NULL
Sequencing	NULL
of	NULL
Rearranged	NULL
TCR	NULL
a	NULL
and	NULL
Sequences	NULL
.	NULL

TCR	NULL
a	NULL
rearranged	NULL
sequences	NULL
were	NULL
amplified	NULL
with	NULL
one	NULL
of	NULL
32	NULL
5	NULL
``	NULL
TCRAV	NULL
family-specific	NULL
oligonucleotides	NULL
(	NULL
Val-32	NULL
)	NULL
and	NULL
a	NULL
3	NULL
'	NULL
TCRAC	NULL
(	NULL
Ca	NULL
)	NULL
constant	NULL
primer	NULL
.	NULL

Amplification	NULL
conditions	NULL
were	NULL
the	NULL
same	NULL
as	NULL
those	NULL
described	NULL
(	NULL
16	NULL
)	NULL
except	NULL
that	NULL
annealing	NULL
was	NULL
performed	NULL
at	NULL
55°C	NULL
.	NULL

The	NULL
oligonucleotides	NULL
Val-12/Val7-18/Ca	NULL
and	NULL
Val3-16/Va22-29/Va32	NULL
were	NULL
synthesized	NULL
according	NULL
to	NULL
Davies	NULL
et	NULL
al	NULL
.	NULL

(	NULL
36	NULL
)	NULL
and	NULL
Steinle	NULL
et	NULL
al	NULL
.	NULL

(	NULL
37	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
Va15	NULL
,	NULL
16	NULL
,	NULL
and	NULL
17	NULL
primers	NULL
reported	NULL
previously	NULL
(	NULL
36	NULL
)	NULL
were	NULL
reassigned	NULL
to	NULL
Val9	NULL
,	NULL
20	NULL
,	NULL
and	NULL
21	NULL
,	NULL
respectively	NULL
,	NULL
in	NULL
accordance	NULL
with	NULL
the	NULL
new	NULL
nomenclature	NULL
(	NULL
38	NULL
)	NULL
.	NULL

TCRAV	NULL
families	NULL
30	NULL
and	NULL
31	NULL
were	NULL
amplified	NULL
with	NULL
the	NULL
following	NULL
oligonucleotides	NULL
:	NULL
Va30	NULL
,	NULL
5	NULL
!	NULL

-CTTCACCCTGTATTCAGCTGGG-3	NULL
'	NULL
;	NULL
Va31	NULL
,	NULL
5'-CTGCAGCTTCTTCAGAGAGAGACAATGG-3	NULL
'	NULL
.	NULL

TCR	NULL
$	NULL
rearranged	NULL
sequences	NULL
were	NULL
amplified	NULL
as	NULL
detailed	NULL
(	NULL
16	NULL
)	NULL
.	NULL

TCRBV25	NULL
was	NULL
amplified	NULL
under	NULL
the	NULL
conditions	NULL
described	NULL
(	NULL
16	NULL
)	NULL
with	NULL
the	NULL
following	NULL
oligonucleotide	NULL
:	NULL
V	NULL
B25	NULL
,	NULL
5-AACAGGTC-CTGAAAAACGAGTTCAA-3	NULL
'	NULL
.	NULL

The	NULL
amplified	NULL
TCRB	NULL
and	NULL
TCRa	NULL
sequences	NULL
were	NULL
purified	NULL
and	NULL
sequenced	NULL
as	NULL
reported	NULL
(	NULL
16	NULL
)	NULL
.	NULL

RESULTS	NULL
AND	NULL
DISCUSSION	NULL
CD8*	NULL
(	NULL
>	NULL
99	NULL
%	NULL
purity	NULL
)	NULL
,	NULL
RAK-reactive	NULL
CTL	NULL
clones	NULL
were	NULL
generated	NULL
from	NULL
an	NULL
HLA-B8*	NULL
healthy	NULL
virus	NULL
carrier	NULL
,	NULL
SP	NULL
.	NULL

Remarkably	NULL
,	NULL
clones	NULL
were	NULL
identified	NULL
that	NULL
also	NULL
crossreacted	NULL
with	NULL
two	NULL
of	NULL
the	NULL
peptide	NULL
homologues	NULL
,	NULL
RSK	NULL
from	NULL
a	NULL
human	NULL
serine/threonine	NULL
kinase	NULL
(	NULL
GenBank	NULL
accession	NULL
P27448	NULL
)	NULL
and	NULL
RRK	NULL
from	NULL
Staphylococcus	NULL
aureus	NULL
replication	NULL
initiation	NULL
protein	NULL
(	NULL
GenBank	NULL
accession	NULL
P14490	NULL
)	NULL
.	NULL

The	NULL
*'Cr-release	NULL
data	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
show	NULL
the	NULL
cytotoxicity	NULL
profiles	NULL
of	NULL
three	NULL
clones	NULL
responding	NULL
to	NULL
HLA-B8	NULL
#	NULL
*	NULL
PHA-blasts	NULL
pulsed	NULL
with	NULL
selected	NULL
peptide	NULL
homologues	NULL
.	NULL

Three	NULL
crossreactivity	NULL
patterns	NULL
were	NULL
distinguished	NULL
:	NULL
(	NULL
¥	NULL
)	NULL
clone	NULL
SP42	NULL
strongly	NULL
lysed	NULL
targets	NULL
pulsed	NULL
with	NULL
RAK	NULL
,	NULL
RSK	NULL
,	NULL
or	NULL
RRK	NULL
peptides	NULL
(	NULL
referred	NULL
to	NULL
as	NULL
triple	NULL
peptide-reactive	NULL
clones	NULL
hereafter	NULL
)	NULL
,	NULL
(	NULL
ii	NULL
)	NULL
clone	NULL
SP35	NULL
recognized	NULL
both	NULL
the	NULL
RAK	NULL
and	NULL
RSK	NULL
peptides	NULL
(	NULL
referred	NULL
to	NULL
as	NULL
double	NULL
peptide-reactive	NULL
clones	NULL
hereafter	NULL
)	NULL
,	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
clone	NULL
SP28	NULL
stringently	NULL
lysed	NULL
targets	NULL
pulsed	NULL
with	NULL
the	NULL
RAK	NULL
peptide	NULL
(	NULL
referred	NULL
to	NULL
as	NULL
single	NULL
peptide-reactive	NULL
clones	NULL
hereafter	NULL
)	NULL
.	NULL

Immunology	NULL
:	NULL
Misko	NULL
et	NULL
al	NULL
.	NULL

Database	NULL
Designation	NULL
Peptide	NULL
Staphylococcus	NULL
aureus	NULL
replication	NULL
initiation	NULL
protein	NULL
(	NULL
269-276	NULL
)	NULL
Human	NULL
leukemia	NULL
inhibitory	NULL
factor	NULL
precursor	NULL
(	NULL
188-195	NULL
)	NULL
Human	NULL
serine/threonine	NULL
protein	NULL
kinase	NULL
(	NULL
156-163	NULL
)	NULL
Mycobacterium	NULL
lepraeDNA	NULL
RRKYEQIT	NULL
LGEYEQIT	NULL
RSKFRQIV	NULL
polymerase	NULL
III	NULL
(	NULL
258-265	NULL
)	NULL
FPEERQLL	NULL
Escherichia	NULL
coli	NULL
catabolite	NULL
gene	NULL
activator	NULL
(	NULL
100-107	NULL
)	NULL
YKKERQLT	NULL
Hepatitis	NULL
B	NULL
virus	NULL
core	NULL
antigen	NULL
(	NULL
94-101	NULL
)	NULL
GLRFRQLL	NULL
Human	NULL
sodium	NULL
channel	NULL
protein	NULL
(	NULL
564-571	NULL
)	NULL
WLRFRNIT	NULL
Epstein-Barr	NULL
virus	NULL
trans-	NULL
activator	NULL
protein	NULL
(	NULL
190-197	NULL
)	NULL
RAKFKQLL	NULL
0	NULL
ao	NULL
-	NULL
«	NULL
00	NULL
0	NULL
60	NULL
0	NULL
so	NULL
-	NULL
100	NULL
%	NULL
Specific	NULL
Lysis	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

-	NULL
Specific	NULL
lysis	NULL
shown	NULL
by	NULL
three	NULL
selected	NULL
CTL	NULL
clones	NULL
generated	NULL
from	NULL
an	NULL
HLA-B8+	NULL
,	NULL
healthy	NULL
virus	NULL
carrier	NULL
SP	NULL
after	NULL
stimulation	NULL
in	NULL
vitro	NULL
of	NULL
PBMCs	NULL
with	NULL
the	NULL
autologous	NULL
LCL	NULL
.	NULL

Clones	NULL
were	NULL
tested	NULL
in	NULL
standard	NULL
4-h	NULL
©'Cr-release	NULL
assays	NULL
against	NULL
autologous	NULL
PHA	NULL
blasts	NULL
pulsed	NULL
with	NULL
the	NULL
BZLF1-associated	NULL
RAK	NULL
peptide	NULL
or	NULL
peptide	NULL
homologues	NULL
derived	NULL
from	NULL
known	NULL
human	NULL
pathogens	NULL
or	NULL
putative	NULL
autoantigens	NULL
,	NULL
as	NULL
listed	NULL
on	NULL
the	NULL
ordinate	NULL
.	NULL

Amino	NULL
acid	NULL
positions	NULL
in	NULL
the	NULL
protein	NULL
sequence	NULL
are	NULL
given	NULL
in	NULL
parentheses	NULL
.	NULL

Triple	NULL
peptide-reactive	NULL
clone	NULL
SP42	NULL
(	NULL
0	NULL
)	NULL
,	NULL
double	NULL
peptide-reactive	NULL
clone	NULL
SP35	NULL
(	NULL
M	NULL
)	NULL
,	NULL
and	NULL
single	NULL
peptide-reactive	NULL
clone	NULL
SP28	NULL
(	NULL
®	NULL
)	NULL
.	NULL

Effector/target	NULL
ratio	NULL
,	NULL
2:1	NULL
.	NULL

The	NULL
discovery	NULL
of	NULL
a	NULL
potential	NULL
self	NULL
peptide	NULL
that	NULL
might	NULL
be	NULL
involved	NULL
in	NULL
positive	NULL
selection	NULL
of	NULL
a	NULL
subpopulation	NULL
of	NULL
RAK-reactive	NULL
CTLs	NULL
prompted	NULL
a	NULL
more	NULL
detailed	NULL
study	NULL
of	NULL
these	NULL
crossreactions	NULL
in	NULL
donor	NULL
SP	NULL
.	NULL

An	NULL
analysis	NULL
of	NULL
220	NULL
CD8*	NULL
,	NULL
RAK-reactive	NULL
CTL	NULL
clones	NULL
provided	NULL
estimates	NULL
of	NULL
the	NULL
abundance	NULL
of	NULL
clones	NULL
belonging	NULL
to	NULL
each	NULL
of	NULL
the	NULL
crossreactivity	NULL
groups	NULL
.	NULL

A	NULL
predominant	NULL
number	NULL
of	NULL
clones	NULL
(	NULL
52.7	NULL
%	NULL
)	NULL
were	NULL
single	NULL
peptide-reactive	NULL
,	NULL
36.8	NULL
%	NULL
of	NULL
the	NULL
clones	NULL
were	NULL
double	NULL
peptide-reactive	NULL
,	NULL
and	NULL
10.5	NULL
%	NULL
were	NULL
triple	NULL
peptide-reactive	NULL
.	NULL

The	NULL
fine	NULL
specificities	NULL
of	NULL
10	NULL
representative	NULL
clones	NULL
from	NULL
each	NULL
group	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
2-c	NULL
.	NULL

The	NULL
EBV	NULL
nuclear	NULL
antigen	NULL
3-encoded	NULL
,	NULL
HLA-B8-restricted	NULL
peptides	NULL
,	NULL
FLRGRAYGL	NULL
and	NULL
QAKWRLQTL	NULL
,	NULL
included	NULL
in	NULL
each	NULL
assay	NULL
as	NULL
specificity	NULL
controls	NULL
,	NULL
were	NULL
not	NULL
recognized	NULL
by	NULL
the	NULL
RAK-reactive	NULL
clones	NULL
.	NULL

The	NULL
abundance	NULL
and	NULL
specificity	NULL
of	NULL
the	NULL
crossreactive	NULL
clones	NULL
made	NULL
it	NULL
highly	NULL
unlikely	NULL
that	NULL
they	NULL
were	NULL
``	NULL
forbidden	NULL
``	NULL
clones	NULL
or	NULL
expressed	NULL
degenerate	NULL
TCR	NULL
recognition	NULL
.	NULL

Instead	NULL
,	NULL
it	NULL
is	NULL
more	NULL
likely	NULL
that	NULL
they	NULL
represent	NULL
a	NULL
subpopulation	NULL
of	NULL
potentially	NULL
autoreactive	NULL
T	NULL
cells	NULL
normally	NULL
found	NULL
in	NULL
the	NULL
periphery	NULL
as	NULL
an	NULL
outcome	NULL
of	NULL
intrathymic	NULL
positive	NULL
selection	NULL
(	NULL
23	NULL
,	NULL
24	NULL
,	NULL
39	NULL
)	NULL
.	NULL

There	NULL
is	NULL
good	NULL
evidence	NULL
that	NULL
positive	NULL
selection	NULL
of	NULL
the	NULL
mature	NULL
T	NULL
cell	NULL
peripheral	NULL
repertoire	NULL
is	NULL
based	NULL
on	NULL
low-avidity	NULL
interactions	NULL
between	NULL
the	NULL
«	NULL
B	NULL
TCR	NULL
on	NULL
thymocytes	NULL
and	NULL
self	NULL
peptide	NULL
ligands	NULL
presented	NULL
by	NULL
MHC	NULL
molecules	NULL
expressed	NULL
on	NULL
thymic	NULL
stromal	NULL
cells	NULL
(	NULL
24	NULL
)	NULL
.	NULL

In	NULL
the	NULL
periphery	NULL
,	NULL
these	NULL
autoreactive	NULL
T	NULL
cells	NULL
would	NULL
only	NULL
be	NULL
weakly-reactive	NULL
to	NULL
self	NULL
peptides	NULL
because	NULL
the	NULL
avidity	NULL
required	NULL
for	NULL
TCR	NULL
activation	NULL
during	NULL
positive	NULL
selection	NULL
of	NULL
thymocytes	NULL
evidently	NULL
is	NULL
lower	NULL
than	NULL
that	NULL
required	NULL
for	NULL
TCR	NULL
activation	NULL
during	NULL
the	NULL
recognition	NULL
of	NULL
antigen	NULL
by	NULL
mature	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
constraints	NULL
on	NULL
autoreactivity	NULL
can	NULL
obviously	NULL
be	NULL
circumvented	NULL
by	NULL
activating	NULL
CTLs	NULL
in	NULL
vitro	NULL
with	NULL
the	NULL
cognate	NULL
peptide	NULL
or	NULL
in	NULL
vivo	NULL
after	NULL
an	NULL
appropriate	NULL
infection	NULL
.	NULL

To	NULL
gain	NULL
insight	NULL
into	NULL
the	NULL
affinity	NULL
properties	NULL
of	NULL
the	NULL
RAK	NULL
,	NULL
RSK	NULL
,	NULL
and	NULL
RRK	NULL
peptides	NULL
,	NULL
we	NULL
characterized	NULL
their	NULL
ability	NULL
to	NULL
sensitize	NULL
target	NULL
cell	NULL
lysis	NULL
by	NULL
testing	NULL
representative	NULL
clones	NULL
selected	NULL
from	NULL
each	NULL
of	NULL
the	NULL
crossreactivity	NULL
groups	NULL
for	NULL
their	NULL
response	NULL
to	NULL
varying	NULL
concentrations	NULL
of	NULL
peptides	NULL
.	NULL

The	NULL
peptide	NULL
titration	NULL
results	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
a-c	NULL
show	NULL
that	NULL
the	NULL
RAK	NULL
peptide	NULL
was	NULL
substantially	NULL
more	NULL
effective	NULL
than	NULL
the	NULL
RSK	NULL
and	NULL
RRK	NULL
peptides	NULL
in	NULL
sensitizing	NULL
targets	NULL
to	NULL
lysis	NULL
,	NULL
and	NULL
that	NULL
all	NULL
clonotypes	NULL
were	NULL
virtually	NULL
equally	NULL
effective	NULL
in	NULL
the	NULL
lysis	NULL
of	NULL
RAK-sensitized	NULL
targets	NULL
.	NULL

However	NULL
,	NULL
the	NULL
RSK	NULL
and	NULL
RRK	NULL
peptide	NULL
concentrations	NULL
required	NULL
for	NULL
optimal	NULL
target	NULL
sensitization	NULL
was	NULL
20-	NULL
to	NULL
30-fold	NULL
higher	NULL
than	NULL
for	NULL
the	NULL
RAK	NULL
peptide	NULL
.	NULL

Another	NULL
difference	NULL
in	NULL
peptide	NULL
recognition	NULL
was	NULL
reflected	NULL
at	NULL
the	NULL
level	NULL
of	NULL
inhibition	NULL
of	NULL
lysis	NULL
with	NULL
anti-class	NULL
I	NULL
mAb	NULL
as	NULL
lysis	NULL
of	NULL
targets	NULL
pulsed	NULL
with	NULL
RSK	NULL
or	NULL
RRK	NULL
peptide	NULL
was	NULL
considerably	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
2281	NULL
i	NULL
i	NULL
@	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
o	NULL
%	NULL
Specific	NULL
Lysis	NULL
bo	NULL
o	NULL
o	NULL
RAK	NULL
RSK	NULL
RRK	NULL
FLR	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Specific	NULL
lysis	NULL
shown	NULL
by	NULL
representative	NULL
triple	NULL
(	NULL
a	NULL
)	NULL
,	NULL
double	NULL
(	NULL
b	NULL
)	NULL
,	NULL
and	NULL
single	NULL
(	NULL
c	NULL
)	NULL
peptide	NULL
-reactive	NULL
CTL	NULL
clones	NULL
generated	NULL
from	NULL
an	NULL
HLA-B8+	NULL
,	NULL
healthy	NULL
virus	NULL
carrier	NULL
SP	NULL
after	NULL
stimulation	NULL
in	NULL
vifro	NULL
of	NULL
PBMCs	NULL
with	NULL
the	NULL
autologous	NULL
LCL	NULL
or	NULL
HLA-A1/B8	NULL
homozygous	NULL
BM	NULL
LCL	NULL
.	NULL

Clones	NULL
were	NULL
tested	NULL
in	NULL
standard	NULL
4-h	NULL
*'Cr-release	NULL
assays	NULL
against	NULL
autologous	NULL
or	NULL
BM	NULL
PHA	NULL
blasts	NULL
pulsed	NULL
with	NULL
RAK	NULL
,	NULL
RSK	NULL
,	NULL
RRK	NULL
,	NULL
FLR	NULL
,	NULL
or	NULL
QAK	NULL
peptide	NULL
,	NULL
or	NULL
without	NULL
added	NULL
peptide	NULL
(	NULL
-	NULL
)	NULL
.	NULL

Effector/target	NULL
ratio	NULL
,	NULL
2:1.	NULL
more	NULL
sensitive	NULL
to	NULL
inhibition	NULL
than	NULL
targets	NULL
pulsed	NULL
with	NULL
the	NULL
RAK	NULL
peptide	NULL
(	NULL
I.S.M	NULL
.	NULL

,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

The	NULL
simplest	NULL
explanation	NULL
for	NULL
these	NULL
differences	NULL
is	NULL
that	NULL
both	NULL
the	NULL
self	NULL
and	NULL
bacterial	NULL
peptides	NULL
behave	NULL
as	NULL
low-affinity	NULL
ligands	NULL
for	NULL
the	NULL
TCR	NULL
expressed	NULL
by	NULL
the	NULL
RAK-reactive	NULL
CTLs	NULL
.	NULL

The	NULL
weaker	NULL
cytotoxic	NULL
responses	NULL
obtained	NULL
with	NULL
limiting	NULL
concentrations	NULL
of	NULL
RSK	NULL
and	NULL
RRK	NULL
peptides	NULL
indicated	NULL
that	NULL
these	NULL
homologues	NULL
also	NULL
might	NULL
behave	NULL
differently	NULL
to	NULL
the	NULL
cognate	NULL
peptide	NULL
at	NULL
the	NULL
level	NULL
of	NULL
activation	NULL
of	NULL
memory	NULL
CTLs	NULL
,	NULL
as	NULL
has	NULL
been	NULL
observed	NULL
with	NULL
altered	NULL
peptide	NULL
ligands	NULL
(	NULL
reviewed	NULL
in	NULL
ref	NULL
.	NULL

40	NULL
)	NULL
.	NULL

Accordingly	NULL
,	NULL
the	NULL
precursor	NULL
frequencies	NULL
of	NULL
memory	NULL
CTLs	NULL
responding	NULL
to	NULL
the	NULL
RAK	NULL
,	NULL
RSK	NULL
,	NULL
and	NULL
RRK	NULL
peptides	NULL
were	NULL
estimated	NULL
by	NULL
limiting	NULL
dilution	NULL
analysis	NULL
of	NULL
PBMCs	NULL
from	NULL
three	NULL
HLA-B8*	NULL
,	NULL
healthy	NULL
virus	NULL
carriers	NULL
.	NULL

The	NULL
limiting	NULL
dilution	NULL
analysis	NULL
outcomes	NULL
for	NULL
donors	NULL
SP	NULL
,	NULL
LC	NULL
,	NULL
and	NULL
MM	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
a	NULL
,	NULL
b	NULL
,	NULL
and	NULL
c	NULL
,	NULL
respectively	NULL
.	NULL

Clearly	NULL
,	NULL
all	NULL
RAK	NULL
peptide-stimulated	NULL
cultures	NULL
showed	NULL
high	NULL
precursor	NULL
frequencies	NULL
of	NULL
CTLs	NULL
that	NULL
recognized	NULL
RAK	NULL
,	NULL
RSK	NULL
,	NULL
or	NULL
RRK	NULL
peptide	NULL
,	NULL
and	NULL
,	NULL
invariably	NULL
,	NULL
the	NULL
highest	NULL
frequencies	NULL
were	NULL
associated	NULL
with	NULL
recognition	NULL
of	NULL
the	NULL
RAK	NULL
peptide	NULL
and	NULL
the	NULL
lowest	NULL
with	NULL
the	NULL
RRK	NULL
peptide	NULL
.	NULL

This	NULL
hierarchy	NULL
confirmed	NULL
the	NULL
clonal	NULL
CTL	NULL
findings	NULL
in	NULL
donor	NULL
SP	NULL
.	NULL

An	NULL
analysis	NULL
of	NULL
individual	NULL
microcultures	NULL
at	NULL
the	NULL
lower	NULL
responder	NULL
cell	NULL
levels	NULL
also	NULL
provided	NULL
evidence	NULL
of	NULL
triple	NULL
peptide-	NULL
,	NULL
double	NULL
peptide-	NULL
,	NULL
and	NULL
single	NULL
peptide-reactive	NULL
CTL	NULL
precursors	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
considerably	NULL
weaker	NULL
frequencies	NULL
were	NULL
detected	NULL
in	NULL
the	NULL
RSK	NULL
peptide-	NULL
and	NULL
RRK	NULL
peptide-stimulated	NULL
cultures	NULL
,	NULL
indicating	NULL
that	NULL
these	NULL
peptides	NULL
were	NULL
poorly	NULL
immunogenic	NULL
in	NULL
activating	NULL
memory	NULL
T	NULL
cells	NULL
.	NULL

We	NULL
verified	NULL
that	NULL
the	NULL
RSK	NULL
peptide	NULL
sequence	NULL
is	NULL
present	NULL
in	NULL
the	NULL
genomic	NULL
DNA	NULL
derived	NULL
from	NULL
2282	NULL
Immunology	NULL
:	NULL
Misko	NULL
et	NULL
al	NULL
.	NULL

100	NULL
80	NULL
60	NULL
40	NULL
RAK	NULL
peptide	NULL
concentration	NULL
(	NULL
1g	NULL
)	NULL
80	NULL
8	NULL
§	NULL
r	NULL
--	NULL
%	NULL
Specific	NULL
Lysis	NULL
to	NULL
©	NULL
RSK	NULL
peptide	NULL
concentration	NULL
(	NULL
1g	NULL
)	NULL
10	NULL
1	NULL
0.1	NULL
0.01	NULL
0.001	NULL
_	NULL
0.0001	NULL
RRK	NULL
peptide	NULL
concentration	NULL
(	NULL
1g	NULL
)	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

-	NULL
Specific	NULL
lysis	NULL
shown	NULL
by	NULL
representative	NULL
triple	NULL
(	NULL
M	NULL
)	NULL
,	NULL
double	NULL
(	NULL
0	NULL
)	NULL
,	NULL
and	NULL
single	NULL
(	NULL
&	NULL
)	NULL
peptide-reactive	NULL
CTL	NULL
clones	NULL
generated	NULL
from	NULL
an	NULL
HLA-B8+	NULL
healthy	NULL
virus	NULL
carrier	NULL
SP	NULL
after	NULL
stimulation	NULL
in	NULL
vifro	NULL
of	NULL
PBMCs	NULL
with	NULL
the	NULL
autologous	NULL
LCL	NULL
or	NULL
HLA-A1/B8	NULL
homozygous	NULL
BM	NULL
LCL	NULL
.	NULL

Clones	NULL
were	NULL
tested	NULL
in	NULL
standard	NULL
4-h	NULL
5'Cr-release	NULL
assays	NULL
against	NULL
autologous	NULL
PHA	NULL
blasts	NULL
pulsed	NULL
with	NULL
varying	NULL
concentrations	NULL
of	NULL
RAK	NULL
(	NULL
a	NULL
)	NULL
,	NULL
RSK	NULL
(	NULL
b	NULL
)	NULL
,	NULL
or	NULL
RRK	NULL
(	NULL
c	NULL
)	NULL
peptide	NULL
.	NULL

Effector/target	NULL
ratio	NULL
,	NULL
2:1.	NULL
the	NULL
autologous	NULL
LCL	NULL
of	NULL
donor	NULL
SP	NULL
(	NULL
I.S.M	NULL
.	NULL

and	NULL
S.C.	NULL
,	NULL
unpublished	NULL
data	NULL
)	NULL
,	NULL
although	NULL
it	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
this	NULL
self	NULL
peptide	NULL
is	NULL
processed	NULL
or	NULL
presented	NULL
naturally	NULL
.	NULL

Nevertheless	NULL
,	NULL
in	NULL
theory	NULL
,	NULL
the	NULL
RSK	NULL
peptide	NULL
could	NULL
behave	NULL
as	NULL
a	NULL
low-affinity	NULL
ligand	NULL
resulting	NULL
only	NULL
in	NULL
the	NULL
weak	NULL
reactivation	NULL
of	NULL
specific	NULL
memory	NULL
T	NULL
cells	NULL
due	NULL
to	NULL
peripheral	NULL
tolerance	NULL
.	NULL

Ligation	NULL
of	NULL
the	NULL
TCR	NULL
by	NULL
altered	NULL
peptide	NULL
ligands	NULL
can	NULL
result	NULL
in	NULL
diminished	NULL
signaling	NULL
events	NULL
involving	NULL
the	NULL
incomplete	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
TCR	NULL
subunits	NULL
and	NULL
no	NULL
activation	NULL
of	NULL
ZAP-70	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Such	NULL
modified	NULL
TCR	NULL
signaling	NULL
,	NULL
particularly	NULL
in	NULL
response	NULL
to	NULL
tolerizing	NULL
peptides	NULL
,	NULL
could	NULL
instigate	NULL
T	NULL
cell	NULL
anergy	NULL
,	NULL
ignorance	NULL
,	NULL
or	NULL
deletion	NULL
,	NULL
rather	NULL
than	NULL
activation	NULL
.	NULL

Intriguingly	NULL
,	NULL
the	NULL
bacterial	NULL
peptide	NULL
behaved	NULL
like	NULL
a	NULL
tolerogenic	NULL
self	NULL
peptide	NULL
.	NULL

Because	NULL
S.	NULL
aureus	NULL
commonly	NULL
forms	NULL
part	NULL
of	NULL
the	NULL
mucosal	NULL
commensal	NULL
flora	NULL
(	NULL
42	NULL
)	NULL
,	NULL
it	NULL
is	NULL
perhaps	NULL
not	NULL
unreasonable	NULL
to	NULL
expect	NULL
that	NULL
host	NULL
T	NULL
cells	NULL
may	NULL
be	NULL
tolerant	NULL
to	NULL
protein	NULL
antigens	NULL
derived	NULL
from	NULL
this	NULL
commensal	NULL
,	NULL
akin	NULL
to	NULL
the	NULL
systemic	NULL
tolerance	NULL
that	NULL
can	NULL
be	NULL
induced	NULL
in	NULL
T	NULL
cells	NULL
by	NULL
antigens	NULL
from	NULL
other	NULL
com-mensals	NULL
such	NULL
as	NULL
enteric	NULL
bacteria	NULL
,	NULL
and	NULL
by	NULL
dietary	NULL
antigens	NULL
(	NULL
43	NULL
,	NULL
44	NULL
)	NULL
.	NULL

%	NULL
\Iext	NULL
,	NULL
we	NULL
defined	NULL
the	NULL
aB	NULL
TCR	NULL
phenotype	NULL
of	NULL
selected	NULL
RAK-reactive	NULL
CTL	NULL
clones	NULL
from	NULL
donor	NULL
SP	NULL
to	NULL
determine	NULL
whether	NULL
there	NULL
was	NULL
a	NULL
structural	NULL
basis	NULL
to	NULL
accommodate	NULL
the	NULL
different	NULL
crossreactivity	NULL
patterns	NULL
observed	NULL
with	NULL
multiple	NULL
peptide	NULL
ligands	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
TCR	NULL
«	NULL
B	NULL
sequences	NULL
,	NULL
identified	NULL
by	NULL
using	NULL
TCRAV	NULL
and	NULL
TCRBV	NULL
family-specific	NULL
PCR	NULL
followed	NULL
by	NULL
direct	NULL
sequencing	NULL
,	NULL
showed	NULL
several	NULL
interesting	NULL
features	NULL
as	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
a	NULL
and	NULL
b	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
predicted	NULL
amino	NULL
acid	NULL
sequences	NULL
of	NULL
all	NULL
triple	NULL
peptide-reactive	NULL
TCRs	NULL
revealed	NULL
identical	NULL
rearrangements	NULL
with	NULL
an	NULL
identical	NULL
complementarity	NULL
determining	NULL
region	NULL
3	NULL
(	NULL
CDR3	NULL
)	NULL
that	NULL
directly	NULL
contacts	NULL
the	NULL
peptide	NULL
epitope	NULL
.	NULL

This	NULL
conserved	NULL
Va	NULL
chain	NULL
was	NULL
paired	NULL
predominantly	NULL
to	NULL
TCRBV7BJ2S7	NULL
;	NULL
clone	NULL
SP4	NULL
was	NULL
paired	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
RAK-stim	NULL
RSK-stim	NULL
RRK-slim	NULL
tak	NULL
mess	NULL
.	NULL

(	NULL
WeAre	NULL
--	NULL
-	NULL
$	NULL
-_	NULL
f	NULL
*	NULL
==-C=	NULL
m0_010'\	NULL
``	NULL
``	NULL
bou	NULL
ob	NULL
du	NULL
Loa	NULL
8	NULL
b	NULL
1.000	NULL
--	NULL
c	NULL
=	NULL
--	NULL
in	NULL
“	NULL
W\\\_	NULL
Tam—Qt	NULL
»	NULL
:	NULL
.5	NULL
\gi	NULL
O	NULL
C	NULL
8-	NULL
d	NULL
a	NULL
9100	NULL
®	NULL
[	NULL
=	NULL
&	NULL
el	NULL
20.010	NULL
1__L__	NULL
Lod	NULL
ob	NULL
ga	NULL
poop	NULL
uud	NULL
8	NULL
C	NULL
§	NULL
1.000	NULL
3:6	NULL
—ﬁu	NULL
9m	NULL
``	NULL
;	NULL
w_	NULL
0	NULL
0.100	NULL
\	NULL
\U	NULL
\	NULL
qc	NULL
c	NULL
uc	NULL
c	NULL
g	NULL
__	NULL
0.010	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
50	NULL
60	NULL
Cells/well	NULL
(	NULL
x	NULL
10°	NULL
)	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Comparative	NULL
CTL	NULL
precursor	NULL
(	NULL
CTL	NULL
,	NULL
)	NULL
frequencies	NULL
in	NULL
PBMCs	NULL
from	NULL
three	NULL
HLA-B8+*	NULL
healthy	NULL
virus	NULL
carriers	NULL
SP	NULL
(	NULL
@	NULL
)	NULL
,	NULL
LC	NULL
(	NULL
b	NULL
)	NULL
,	NULL
and	NULL
MM	NULL
(	NULL
c	NULL
)	NULL
by	NULL
using	NULL
limiting	NULL
dilution	NULL
analysis	NULL
.	NULL

PBMCs	NULL
were	NULL
stimulated	NULL
with	NULL
autologous	NULL
PHA	NULL
blasts	NULL
pulsed	NULL
with	NULL
RAK	NULL
,	NULL
RSK	NULL
,	NULL
or	NULL
RRK	NULL
peptide	NULL
.	NULL

The	NULL
frequency	NULL
of	NULL
CTL	NULL
,	NULL
,	NULL
responding	NULL
to	NULL
individual	NULL
peptides	NULL
was	NULL
estimated	NULL
from	NULL
split-well	NULL
assays	NULL
by	NULL
using	NULL
standard	NULL
4-h	NULL
*'Cr-release	NULL
assays	NULL
and	NULL
autologous	NULL
or	NULL
BM	NULL
PHA	NULL
blast	NULL
targets	NULL
pulsed	NULL
with	NULL
RAK	NULL
(	NULL
0	NULL
)	NULL
,	NULL
RSK	NULL
(	NULL
A	NULL
)	NULL
,	NULL
or	NULL
RRK	NULL
(	NULL
0	NULL
)	NULL
peptide	NULL
.	NULL

to	NULL
TCRBV6BJ2S7	NULL
and	NULL
used	NULL
a	NULL
distinct	NULL
VB	NULL
chain	NULL
CDR3	NULL
sequence	NULL
,	NULL
although	NULL
there	NULL
was	NULL
a	NULL
constrained	NULL
maintenance	NULL
of	NULL
CDR3	NULL
loop	NULL
length	NULL
,	NULL
indicating	NULL
antigen-driven	NULL
selection	NULL
.	NULL

The	NULL
detection	NULL
of	NULL
triple	NULL
peptide-reactive	NULL
CTL	NULL
clones	NULL
with	NULL
identical	NULL
TCRs	NULL
is	NULL
not	NULL
simply	NULL
due	NULL
to	NULL
the	NULL
amplification	NULL
in	NULL
vitro	NULL
of	NULL
sister	NULL
clones	NULL
because	NULL
the	NULL
precursor	NULL
T	NULL
cells	NULL
giving	NULL
rise	NULL
to	NULL
these	NULL
clones	NULL
were	NULL
initially	NULL
stimulated	NULL
in	NULL
separate	NULL
cultures	NULL
before	NULL
agar	NULL
cloning	NULL
.	NULL

Also	NULL
,	NULL
the	NULL
recurrent	NULL
«	NULL
B	NULL
TCR	NULL
expressed	NULL
by	NULL
the	NULL
triple	NULL
peptide-reactive	NULL
clones	NULL
was	NULL
found	NULL
in	NULL
donor	NULL
SP	NULL
on	NULL
three	NULL
separate	NULL
occasions	NULL
.	NULL

By	NULL
comparison	NULL
,	NULL
the	NULL
double	NULL
peptide-reactive	NULL
TCRs	NULL
showed	NULL
sequence	NULL
variation	NULL
,	NULL
albeit	NULL
limited	NULL
,	NULL
in	NULL
both	NULL
the	NULL
Va	NULL
and	NULL
VB	NULL
chains	NULL
.	NULL

Nonetheless	NULL
,	NULL
clones	NULL
expressing	NULL
identical	NULL
TCRs	NULL
were	NULL
identified	NULL
.	NULL

Of	NULL
interest	NULL
,	NULL
clone	NULL
SP1	NULL
expressed	NULL
a	NULL
VB	NULL
chain	NULL
identical	NULL
with	NULL
that	NULL
of	NULL
the	NULL
conserved	NULL
triple	NULL
peptide-reactive	NULL
TCR	NULL
,	NULL
but	NULL
was	NULL
paired	NULL
to	NULL
a	NULL
different	NULL
Va	NULL
chain	NULL
,	NULL
confirming	NULL
the	NULL
triple	NULL
peptide-reactive	NULL
TCR	NULL
findings	NULL
that	NULL
the	NULL
Va	NULL
chain	NULL
is	NULL
important	NULL
in	NULL
the	NULL
specific	NULL
recognition	NULL
of	NULL
the	NULL
bacterial	NULL
peptide	NULL
.	NULL

Analysis	NULL
of	NULL
single	NULL
peptide-reactive	NULL
clones	NULL
revealed	NULL
no	NULL
identical	NULL
Va/V	NULL
rearrangements	NULL
,	NULL
and	NULL
each	NULL
clono-type	NULL
expressed	NULL
a	NULL
distinct	NULL
CDR3	NULL
amino	NULL
acid	NULL
composition	NULL
of	NULL
variable	NULL
length	NULL
.	NULL

This	NULL
outcome	NULL
resembled	NULL
the	NULL
broad	NULL
diversity	NULL
obtained	NULL
in	NULL
an	NULL
earlier	NULL
TCR	NULL
VB	NULL
analysis	NULL
of	NULL
RAK-reactive	NULL
clonotypes	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Constraints	NULL
on	NULL
the	NULL
structural	NULL
plasticity	NULL
of	NULL
the	NULL
triple	NULL
peptide-reactive	NULL
TCRs	NULL
were	NULL
also	NULL
obvious	NULL
at	NULL
the	NULL
level	NULL
of	NULL
epitope	NULL
recognition	NULL
as	NULL
determined	NULL
by	NULL
using	NULL
peptide	NULL
analogues	NULL
in	NULL
which	NULL
each	NULL
residue	NULL
of	NULL
RAKFKQLLQ	NULL
was	NULL
sequentially	NULL
substituted	NULL
by	NULL
alanine	NULL
.	NULL

Not	NULL
surprisingly	NULL
,	NULL
all	NULL
triple	NULL
peptide-reactive	NULL
clones	NULL
interacted	NULL
uniformly	NULL
and	NULL
uniquely	NULL
with	NULL
the	NULL
alanine	NULL
replacement	NULL
set	NULL
in	NULL
that	NULL
substitutions	NULL
were	NULL
not	NULL
tolerated	NULL
at	NULL
positions	NULL
3	NULL
,	NULL
4	NULL
,	NULL
6	NULL
,	NULL
and	NULL
7	NULL
while	NULL
the	NULL
fine	NULL
specificity	NULL
patterns	NULL
of	NULL
the	NULL
double	NULL
peptide-	NULL
and	NULL
,	NULL
particularly	NULL
,	NULL
the	NULL
single	NULL
peptide-reactive	NULL
clones	NULL
showed	NULL
multiple	NULL
profiles	NULL
,	NULL
although	NULL
all	NULL
RAK-reactive	NULL
clones	NULL
were	NULL
equally	NULL
sensitive	NULL
to	NULL
substitution	NULL
at	NULL
position	NULL
4	NULL
,	NULL
which	NULL
may	NULL
represent	NULL
a	NULL
critical	NULL
TCR	NULL
contact	NULL
site	NULL
(	NULL
L.S.M	NULL
.	NULL

,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

Overall	NULL
,	NULL
the	NULL
TCR	NULL
data	NULL
clearly	NULL
demonstrate	NULL
that	NULL
a	NULL
diverse	NULL
RAK-reactive	NULL
TCR	NULL
repertoire	NULL
can	NULL
be	NULL
partitioned	NULL
and	NULL
shaped	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
focused	NULL
crossreactions	NULL
with	NULL
Immunology	NULL
:	NULL
Misko	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
a	NULL
Cm	NULL
TCRaV	NULL
FW	NULL
Cords	NULL
rw	NULL
Teras	NULL
cors	NULL
Length	NULL
S93	NULL
,	NULL
4	NULL
,	NULL
18,00	NULL
Avi	NULL
C	NULL
A	NULL
of	NULL
o	NULL
wo	NULL
ow	NULL
9	NULL
os	NULL
os	NULL
ov	NULL
ook	NULL
oL	NULL
ce	NULL
asiess	NULL
a	NULL
24	NULL
,	NULL
27	NULL
,	NULL
42	NULL
tgt	NULL
get	NULL
acg	NULL
tgg	NULL
ang	NULL
gat	NULL
ago	NULL
ago	NULL
tat	NULL
ama	NULL
tog	NULL
ate	NULL
tre	NULL
ggg	NULL
rar/REX/*®	NULL
SP1	NULL
,	NULL
12	NULL
,	NULL
14	NULL
,	NULL
Avia	NULL
C0	NULL
A	NULL
0G	NULL
A	NULL
Do	NULL
R	NULL
D	NULL
D	NULL
Xx	NULL
of	NULL
Dor	NULL
s	NULL
sa	NULL
7	NULL
16	NULL
,	NULL
23235	NULL
ege	NULL
linki	NULL
goa	NULL
gga	NULL
gog	NULL
gac	NULL
aga	NULL
gat	NULL
gac	NULL
aag	NULL
atc	NULL
atc	NULL
ttt	NULL
gga	NULL
spi7	NULL
avir	NULL
C0	NULL
A_	NULL
A	NULL
$	NULL
000	NULL
w	NULL
g	NULL
00	NULL
N	NULL
or	NULL
¥	NULL
G	NULL
Apirse	NULL
7	NULL
tgt	NULL
gea	NULL
goa	NULL
.	NULL

age	NULL
gga	NULL
aat	NULL
ggt	NULL
cag	NULL
aat	NULL
ttt	NULL
gee	NULL
tet	NULL
ggt	NULL
sprs	NULL
avis	NULL
C0	NULL
Ao	NULL
A	NULL
Por	NULL
§	NULL
s	NULL
aA	NULL
p	NULL
c	NULL
L	NULL
T	NULL
G	NULL
ages	NULL
?	NULL

3	NULL
tgt	NULL
got	NULL
gto	NULL
geo	NULL
cee	NULL
coa	NULL
gga	NULL
ggt	NULL
got	NULL
gac	NULL
gga	NULL
ctc	NULL
ace	NULL
ttt	NULL
gge	NULL
RAK/*/*	NULL
sp2	NULL
Avis	NULL
C0	NULL
A0	NULL
R00	NULL
$	NULL
0	NULL
%	NULL
of	NULL
G	NULL
A	NULL
¥	NULL
ow	NULL
on	NULL
PoP	NULL
OS	NULL
0	NULL
ayirgs	NULL
a	NULL
tgt	NULL
gea	NULL
gag	NULL
-	NULL
agt	NULL
gaa	NULL
act	NULL
ggg	NULL
goa	NULL
aac	NULL
aac	NULL
ctc	NULL
tte	NULL
ttt	NULL
999	NULL
vae	NULL
C0	NULL
A	NULL
vo	NULL
£0	NULL
§	NULL
or	NULL
L	NULL
§	NULL
or	NULL
POB	NULL
ob	NULL
OL	NULL
A	NULL
0	NULL
10	NULL
tgt	NULL
get	NULL
gte	NULL
aag	NULL
ago	NULL
ccc	NULL
ctt	NULL
tot	NULL
aga	NULL
egg	NULL
cca	NULL
gam	NULL
ctg	NULL
cto	NULL
ttt	NULL
goa	NULL
sre	NULL
ave	NULL
C0	NULL
L	NULL
Yo	NULL
§	NULL
%	NULL
f	NULL
tf	NULL
b	NULL
bow	NULL
or	NULL
B	NULL
aris	NULL
?	NULL

a	NULL
tye	NULL
cte	NULL
gtg	NULL
gyt	NULL
gaa	NULL
ata	NULL
act	NULL
gat	NULL
gac	NULL
aty	NULL
ogo	NULL
ttt	NULL
gga	NULL
gea	NULL
sps	NULL
ava	NULL
C0	NULL
A/	NULL
V	NULL
s	NULL
)	NULL
T	NULL
r	NULL
G	NULL
60	NULL
500	NULL
I	NULL
G	NULL
Ajss	NULL
?	NULL

10	NULL
tgt	NULL
gee	NULL
gig	NULL
agt	NULL
acy	NULL
gam	NULL
gga	NULL
gga	NULL
ggt	NULL
got	NULL
gac	NULL
gga	NULL
cte	NULL
acc	NULL
ttt	NULL
ggc	NULL
spz0	NULL
avis	NULL
C0	NULL
A	NULL
oB	NULL
woo®	NULL
Of	NULL
s	NULL
¥	NULL
b	NULL
k	NULL
v	NULL
I	NULL
G	NULL
agiss3	NULL
s	NULL
tgt	NULL
goa	NULL
gag	NULL
atg	NULL
gaa	NULL
acc	NULL
toc	NULL
tac	NULL
gac	NULL
aag	NULL
gtg	NULL
ata	NULL
ttt	NULL
999	NULL
spas	NULL
avi	NULL
C0	NULL
A	NULL
V	NULL
P	NULL
$	NULL
0	NULL
G0	NULL
§	NULL
)	NULL
A	NULL
R	NULL
g	NULL
%	NULL
asiess	NULL
a	NULL
tge	NULL
got	NULL
gtt	NULL
ttt	NULL
tot	NULL
ggt	NULL
tot	NULL
goa	NULL
agg	NULL
caa	NULL
ctg	NULL
ace	NULL
ttt	NULL
gga	NULL
avap	NULL
C0	NULL
A	NULL
Wo	NULL
oof	NULL
®	NULL
§	NULL
e	NULL
f	NULL
v	NULL
k	NULL
v	NULL
L	NULL
oor	NULL
amutsio	NULL
a	NULL
tgt	NULL
gee	NULL
gta	NULL
acc	NULL
coe	NULL
toa	NULL
gga	NULL
acc	NULL
tac	NULL
ama	NULL
tac	NULL
atc	NULL
ttt	NULL
gga	NULL
b	NULL
om	NULL
tcray	NULL
rw	NULL
coms	NULL
rm	NULL
rerag	NULL
cous	NULL
Length	NULL
rax/rsx/zex	NULL
§P10,18,24	NULL
.	NULL

gyq	NULL
Co	NULL
A	NULL
0	NULL
80080	NULL
Q	NULL
K	NULL
G	NULL
Q	NULL
UL	NULL
voor	NULL
oa	NULL
x00	NULL
F	NULL
90	NULL
arnst	NULL
ao	NULL
26,27	NULL
,	NULL
42	NULL
tyc	NULL
gee	NULL
age	NULL
ago	NULL
caa	NULL
ama	NULL
gym	NULL
cag	NULL
tty	NULL
toc	NULL
tac	NULL
gag	NULL
cag	NULL
tac	NULL
ttc	NULL
g99	NULL
spa	NULL
mvs	NULL
C0	NULL
A	NULL
S00	NULL
80	NULL
P	NULL
r	NULL
s	NULL
q	NULL
6	NULL
woov	NULL
q	NULL
Yoor	NULL
$	NULL
0	NULL
angoou	NULL
tgt	NULL
gee	NULL
age	NULL
age	NULL
coc	NULL
cog	NULL
ggm	NULL
cag	NULL
ggg	NULL
att	NULL
aac	NULL
tac	NULL
gag	NULL
cag	NULL
tac	NULL
tte	NULL
g99	NULL
RAK/RSE/*	NULL
SPi2	NULL
.	NULL

16.00	NULL
myz	NULL
C0	NULL
A	NULL
soo	NULL
wo	NULL
g	NULL
f	NULL
o	NULL
L	NULL
a	NULL
e	NULL
c	NULL
r	NULL
:	NULL
q	NULL
roof	NULL
G0	NULL
ou	NULL
13	NULL
,	NULL
3s	NULL
tgt	NULL
geo	NULL
age	NULL
age	NULL
cat	NULL
caa	NULL
ace	NULL
gga	NULL
cta	NULL
gea	NULL
gga	NULL
999	NULL
gag	NULL
cag	NULL
tts	NULL
tte	NULL
gag	NULL
spi	NULL
mv	NULL
?	NULL

©	NULL
)	NULL
A	NULL
_	NULL
$	NULL
0	NULL
s	NULL
)	NULL
q	NULL
f	NULL
s	NULL
6	NULL
_	NULL
mpast	NULL
10	NULL
tgo	NULL
gee	NULL
age	NULL
age	NULL
cas	NULL
ama	NULL
gga	NULL
cag	NULL
tty	NULL
toc	NULL
tac	NULL
gag	NULL
cag	NULL
tac	NULL
tte	NULL
999	NULL
sp7	NULL
avi	NULL
C0	NULL
A	NULL
A	NULL
P	NULL
R	NULL
s	NULL
I	NULL
6	NULL
#	NULL
f	NULL
e	NULL
%	NULL
:	NULL
i	NULL
f	NULL
of	NULL
<	NULL
/	NULL
sps	NULL
ou	NULL
tgt	NULL
gee	NULL
age	NULL
agt	NULL
thy	NULL
yea	NULL
ttt	NULL
agg	NULL
tot	NULL
att	NULL
ggg	NULL
ame	NULL
aco	NULL
ggg	NULL
gag	NULL
otg	NULL
CCt	NULL
ttt	NULL
gga	NULL
sp17	NULL
avr	NULL
C0	NULL
)	NULL
A	NULL
s	NULL
&	NULL
ob	NULL
voor	NULL
s	NULL
6	NULL
®	NULL
p	NULL
w	NULL
&	NULL
q	NULL
or	NULL
-	NULL
ars	NULL
:	NULL
ou	NULL
Ege	NULL
geo	NULL
age	NULL
age	NULL
caa	NULL
gge	NULL
cta	NULL
gta	NULL
act	NULL
age	NULL
ggt	NULL
cg9	NULL
gac	NULL
amt	NULL
gag	NULL
Cag	NULL
ttt	NULL
ttt	NULL
gga	NULL
sers	NULL
mye	NULL
UD	NULL
§00	NULL
v	NULL
_	NULL
wo	NULL
f	NULL
G	NULL
)	NULL
®	NULL
w	NULL
b	NULL
o	NULL
%	NULL
x	NULL
$	NULL
os	NULL
tog	NULL
age	NULL
gty	NULL
aac	NULL
aca	NULL
ggg	NULL
gaa	NULL
tgg	NULL
gac	NULL
gag	NULL
cag	NULL
tac	NULL
tte	NULL
g99	NULL
RAK/*	NULL
/*	NULL
sp2	NULL
avir	NULL
C0	NULL
A_	NULL
I	NULL
S0	NULL
5	NULL
Ho	NULL
K	NULL
%	NULL
oT	NULL
c	NULL
t	NULL
:	NULL
aA	NULL
r	NULL
6	NULL
ann	NULL
oii	NULL
tgt	NULL
gos	NULL
atc	NULL
agt	NULL
gac	NULL
cat	NULL
aag	NULL
agg	NULL
aca	NULL
ggg	NULL
ggC	NULL
act	NULL
gam	NULL
got	NULL
tte	NULL
ttt	NULL
gga	NULL
spe	NULL
mye	NULL
CO	NULL
A	NULL
_	NULL
$	NULL
00	NULL
v	NULL
OL	NULL
L	NULL
A	NULL
@	NULL
0	NULL
P	NULL
f	NULL
0	NULL
f	NULL
40	NULL
argo	NULL
ar	NULL
tgt	NULL
goo	NULL
age	NULL
age	NULL
tta	NULL
gtt	NULL
cte	NULL
cta	NULL
gog	NULL
ggg	NULL
coo	NULL
aca	NULL
gat	NULL
acg	NULL
cag	NULL
tat	NULL
ttt	NULL
gga	NULL
spzo	NULL
mve	NULL
©	NULL
_	NULL
A	NULL
_	NULL
S00	NULL
50080	NULL
fo	NULL
A	NULL
s	NULL
G0	NULL
L	NULL
a	NULL
a	NULL
P	NULL
or	NULL
r	NULL
&	NULL
_	NULL
mrrs	NULL
:	NULL
ar	NULL
tgt	NULL
gee	NULL
age	NULL
age	NULL
tea	NULL
act	NULL
get	NULL
cog	NULL
gga	NULL
cta	NULL
gog	NULL
gym	NULL
ttc	NULL
cgg	NULL
cag	NULL
tac	NULL
tte	NULL
gag	NULL
spas	NULL
via	NULL
C0	NULL
A	NULL
_	NULL
S00	NULL
S0	NULL
s	NULL
5	NULL
ra	NULL
&	NULL
fos	NULL
§	NULL
to	NULL
I	NULL
%	NULL
o	NULL
f	NULL
'Go	NULL
ann	NULL
u	NULL
bgt	NULL
gee	NULL
age	NULL
agt	NULL
coo	NULL
cta	NULL
gam	NULL
too	NULL
gac	NULL
agg	NULL
ggg	NULL
act	NULL
gum	NULL
aac	NULL
acc	NULL
ata	NULL
tat	NULL
ttt	NULL
gga	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

V-	NULL
(	NULL
D	NULL
)	NULL
-J	NULL
junctional	NULL
region	NULL
sequences	NULL
of	NULL
a	NULL
(	NULL
a	NULL
)	NULL
and	NULL
B	NULL
(	NULL
b	NULL
)	NULL
chains	NULL
expressed	NULL
by	NULL
triple-peptide	NULL
(	NULL
RAK/RSK/RRK	NULL
)	NULL
,	NULL
double-peptide	NULL
(	NULL
RAK/RSK/*	NULL
)	NULL
,	NULL
or	NULL
single-peptide	NULL
(	NULL
RAK/*/*	NULL
)	NULL
reactive	NULL
CTL	NULL
clones	NULL
generated	NULL
from	NULL
an	NULL
HLA-B8+*	NULL
healthy	NULL
virus	NULL
carrier	NULL
SP	NULL
.	NULL

A	NULL
translated	NULL
amino	NULL
acid	NULL
sequence	NULL
is	NULL
shown	NULL
above	NULL
each	NULL
corresponding	NULL
nucleotide	NULL
sequence	NULL
that	NULL
extended	NULL
at	NULL
least	NULL
70	NULL
nucleotides	NULL
further	NULL
5	NULL
``	NULL
of	NULL
the	NULL
sequence	NULL
shown	NULL
.	NULL

CTL	NULL
clones	NULL
are	NULL
listed	NULL
on	NULL
the	NULL
ordinate	NULL
and	NULL
those	NULL
expressing	NULL
identical	NULL
TCR	NULL
sequences	NULL
are	NULL
grouped	NULL
together	NULL
.	NULL

For	NULL
each	NULL
clone	NULL
,	NULL
the	NULL
deduced	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
CDR3	NULL
loop	NULL
is	NULL
shown	NULL
putatively	NULL
supported	NULL
by	NULL
two	NULL
framework	NULL
branches	NULL
(	NULL
FW	NULL
)	NULL
and	NULL
the	NULL
CDR3	NULL
amino	NULL
acid	NULL
length	NULL
is	NULL
reported	NULL
.	NULL

For	NULL
certain	NULL
clones	NULL
only	NULL
the	NULL
a	NULL
chain	NULL
or	NULL
B	NULL
chain	NULL
sequence	NULL
was	NULL
determined	NULL
.	NULL

peptide	NULL
homologues	NULL
derived	NULL
from	NULL
an	NULL
autoantigen	NULL
and	NULL
an	NULL
environmental	NULL
bacterial	NULL
antigen	NULL
.	NULL

However	NULL
,	NULL
by	NULL
extending	NULL
the	NULL
limited	NULL
panel	NULL
of	NULL
homologues	NULL
used	NULL
in	NULL
this	NULL
study	NULL
,	NULL
we	NULL
anticipate	NULL
that	NULL
additional	NULL
crossreactive	NULL
peptides	NULL
will	NULL
be	NULL
discovered	NULL
,	NULL
some	NULL
of	NULL
which	NULL
may	NULL
be	NULL
responsible	NULL
for	NULL
further	NULL
partitioning	NULL
of	NULL
the	NULL
diverse	NULL
RAK-reactive	NULL
repertoire	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
finding	NULL
of	NULL
recurrent	NULL
TCRs	NULL
,	NULL
combined	NULL
with	NULL
the	NULL
three	NULL
distinct	NULL
patterns	NULL
of	NULL
killing	NULL
shown	NULL
by	NULL
the	NULL
RAK-reactive	NULL
CTLs	NULL
,	NULL
suggests	NULL
that	NULL
clonal	NULL
expansion	NULL
of	NULL
the	NULL
triple	NULL
peptide-reactive	NULL
CTLs	NULL
is	NULL
antigen	NULL
driven	NULL
and	NULL
not	NULL
simply	NULL
an	NULL
outcome	NULL
of	NULL
fortuitous	NULL
crossreactions	NULL
generated	NULL
in	NULL
culture	NULL
.	NULL

To	NULL
explain	NULL
this	NULL
finding	NULL
,	NULL
it	NULL
is	NULL
plausible	NULL
to	NULL
assume	NULL
that	NULL
T	NULL
cells	NULL
are	NULL
normally	NULL
tolerant	NULL
to	NULL
the	NULL
self	NULL
and	NULL
bacterial	NULL
peptides	NULL
due	NULL
to	NULL
peripheral	NULL
and	NULL
mucosal	NULL
tolerance	NULL
,	NULL
respectively	NULL
.	NULL

Because	NULL
low-avidity	NULL
interactions	NULL
between	NULL
TCR	NULL
and	NULL
self	NULL
peptide/MHC	NULL
molecules	NULL
have	NULL
been	NULL
implicated	NULL
recently	NULL
in	NULL
the	NULL
long-term	NULL
survival	NULL
in	NULL
vivo	NULL
of	NULL
naive	NULL
and	NULL
memory	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
cognate	NULL
antigen	NULL
(	NULL
45	NULL
,	NULL
46	NULL
)	NULL
,	NULL
the	NULL
bacterial	NULL
peptide	NULL
could	NULL
perform	NULL
a	NULL
similar	NULL
role	NULL
in	NULL
contributing	NULL
to	NULL
the	NULL
maintenance	NULL
and	NULL
survival	NULL
of	NULL
a	NULL
pool	NULL
of	NULL
triple	NULL
peptide-reactive	NULL
CTL	NULL
precursors	NULL
.	NULL

Precisely	NULL
how	NULL
the	NULL
self	NULL
and	NULL
bacterial	NULL
peptides	NULL
``	NULL
cross-prime	NULL
``	NULL
RAK-reactive	NULL
CTLs	NULL
is	NULL
conjectural	NULL
,	NULL
although	NULL
relevant	NULL
clues	NULL
may	NULL
be	NULL
found	NULL
in	NULL
the	NULL
common	NULL
topography	NULL
of	NULL
intermittent	NULL
S.	NULL
aureus	NULL
and	NULL
persistent	NULL
EBV	NULL
co-infections	NULL
in	NULL
mucosal	NULL
regions	NULL
such	NULL
as	NULL
the	NULL
nasopharynx	NULL
and	NULL
tonsillar	NULL
lymphoepithelium	NULL
.	NULL

Importantly	NULL
,	NULL
tolerance	NULL
to	NULL
the	NULL
self	NULL
peptide	NULL
could	NULL
be	NULL
disrupted	NULL
periodically	NULL
by	NULL
molecular	NULL
mimicry	NULL
or	NULL
bystander	NULL
activation	NULL
at	NULL
sites	NULL
of	NULL
inflammation	NULL
during	NULL
an	NULL
immune	NULL
response	NULL
to	NULL
recru-descent	NULL
EBV	NULL
,	NULL
and	NULL
to	NULL
the	NULL
bacterial	NULL
peptide	NULL
during	NULL
a	NULL
skin	NULL
or	NULL
invasive	NULL
infection	NULL
with	NULL
S.	NULL
aureus	NULL
.	NULL

Available	NULL
abundant	NULL
bacterial	NULL
and	NULL
self	NULL
antigens	NULL
ostensibly	NULL
could	NULL
then	NULL
be	NULL
processed	NULL
by	NULL
den	NULL
dritic	NULL
cells	NULL
through	NULL
an	NULL
exogenous	NULL
vacuolar	NULL
class	NULL
I	NULL
pathway	NULL
for	NULL
presentation	NULL
to	NULL
CD8+*	NULL
T	NULL
cells	NULL
(	NULL
47	NULL
,	NULL
48	NULL
)	NULL
,	NULL
either	NULL
locally	NULL
in	NULL
the	NULL
peripheral	NULL
tissue	NULL
if	NULL
the	NULL
T	NULL
cells	NULL
have	NULL
been	NULL
preactivated	NULL
by	NULL
the	NULL
cognate	NULL
peptide	NULL
or	NULL
in	NULL
the	NULL
regional	NULL
lymph	NULL
nodes	NULL
if	NULL
they	NULL
are	NULL
naive	NULL
or	NULL
resting	NULL
memory	NULL
cells	NULL
,	NULL
thereby	NULL
resulting	NULL
in	NULL
their	NULL
clonal	NULL
expansion	NULL
.	NULL

Such	NULL
clonal	NULL
expansions	NULL
could	NULL
presumably	NULL
take	NULL
place	NULL
before	NULL
a	NULL
primary	NULL
infection	NULL
with	NULL
EBV	NULL
resulting	NULL
in	NULL
a	NULL
high	NULL
frequency	NULL
of	NULL
naive	NULL
RAK-reactive	NULL
CTL	NULL
precursors	NULL
poised	NULL
to	NULL
recognize	NULL
the	NULL
cognate	NULL
peptide	NULL
.	NULL

Indeed	NULL
,	NULL
we	NULL
have	NULL
found	NULL
that	NULL
a	NULL
dominant	NULL
polyclonal	NULL
response	NULL
of	NULL
in	NULL
vivo-activated	NULL
RAK-reactive	NULL
CTLs	NULL
derived	NULL
from	NULL
an	NULL
HLA-B8*	NULL
acute	NULL
infectious	NULL
mononucleosis	NULL
donor	NULL
included	NULL
clones	NULL
that	NULL
strongly	NULL
crossreacted	NULL
with	NULL
the	NULL
RSK	NULL
and	NULL
RRK	NULL
peptides	NULL
(	NULL
LS.M	NULL
.	NULL

,	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
it	NULL
will	NULL
be	NULL
interesting	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
exceptionally	NULL
dominant	NULL
,	NULL
polyclonal	NULL
RAK-reactive	NULL
responses	NULL
that	NULL
have	NULL
been	NULL
identified	NULL
in	NULL
acute	NULL
infectious	NULL
mononucleosis	NULL
donors	NULL
by	NULL
using	NULL
tetramer	NULL
technology	NULL
(	NULL
7	NULL
)	NULL
also	NULL
consist	NULL
of	NULL
clones	NULL
crossreactive	NULL
for	NULL
multiple	NULL
peptide	NULL
ligands	NULL
.	NULL

Future	NULL
studies	NULL
with	NULL
tetramers	NULL
should	NULL
clarify	NULL
the	NULL
importance	NULL
of	NULL
crossreactions	NULL
in	NULL
imprinting	NULL
and	NULL
selection	NULL
of	NULL
the	NULL
peripheral	NULL
TCR	NULL
repertoire	NULL
responsive	NULL
to	NULL
the	NULL
immunodominant	NULL
RAK	NULL
peptide	NULL
.	NULL

Potentially	NULL
self-reactive	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
periphery	NULL
are	NULL
obviously	NULL
kept	NULL
under	NULL
rigorous	NULL
control	NULL
by	NULL
self-tolerance	NULL
and	NULL
ordinarily	NULL
would	NULL
not	NULL
be	NULL
expected	NULL
to	NULL
pose	NULL
an	NULL
autoimmune	NULL
threat	NULL
.	NULL

Thus	NULL
in	NULL
the	NULL
context	NULL
of	NULL
this	NULL
study	NULL
,	NULL
the	NULL
viral	NULL
peptide	NULL
,	NULL
but	NULL
not	NULL
the	NULL
self	NULL
peptide	NULL
,	NULL
was	NULL
effective	NULL
in	NULL
the	NULL
reactivation	NULL
in	NULL
vitro	NULL
of	NULL
RAK-reactive	NULL
memory	NULL
T	NULL
cells	NULL
.	NULL

However	NULL
,	NULL
once	NULL
activated	NULL
by	NULL
the	NULL
cognate	NULL
peptide	NULL
,	NULL
crossreactive	NULL
CTLs	NULL
,	NULL
if	NULL
present	NULL
in	NULL
sufficient	NULL
numbers	NULL
and	NULL
in	NULL
conditions	NULL
of	NULL
abundant	NULL
self/bacterial	NULL
antigen	NULL
presentation	NULL
,	NULL
could	NULL
conceivably	NULL
contribute	NULL
by	NULL
cytokine	NULL
release	NULL
or	NULL
cytolytic	NULL
activity	NULL
to	NULL
the	NULL
immunopathology	NULL
at	NULL
sites	NULL
of	NULL
sus-	NULL
2284	NULL
Immunology	NULL
:	NULL
Misko	NULL
et	NULL
al	NULL
.	NULL

tained	NULL
inflammation	NULL
.	NULL

Indeed	NULL
,	NULL
it	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
the	NULL
BZLF1-specific	NULL
CTLs	NULL
found	NULL
in	NULL
considerable	NULL
numbers	NULL
in	NULL
the	NULL
afflicted	NULL
joints	NULL
of	NULL
patients	NULL
with	NULL
chronic	NULL
rheumatoid	NULL
arthritis	NULL
exacerbate	NULL
disease	NULL
(	NULL
49	NULL
)	NULL
.	NULL

Although	NULL
there	NULL
is	NULL
evidence	NULL
of	NULL
EBV	NULL
infection	NULL
in	NULL
synovial	NULL
tissue	NULL
(	NULL
50	NULL
)	NULL
,	NULL
implying	NULL
that	NULL
the	NULL
antiviral	NULL
CTLs	NULL
could	NULL
be	NULL
responding	NULL
to	NULL
local	NULL
antigenic	NULL
stimulation	NULL
,	NULL
the	NULL
detection	NULL
of	NULL
latent	NULL
or	NULL
lytic	NULL
EBV	NULL
infection	NULL
can	NULL
be	NULL
infrequent	NULL
(	NULL
51	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
absence	NULL
of	NULL
EBV	NULL
could	NULL
simply	NULL
indicate	NULL
that	NULL
an	NULL
earlier	NULL
infection	NULL
had	NULL
been	NULL
cleared	NULL
by	NULL
CTL	NULL
intervention	NULL
.	NULL

This	NULL
outcome	NULL
could	NULL
be	NULL
expected	NULL
if	NULL
there	NULL
was	NULL
a	NULL
dominant	NULL
presence	NULL
of	NULL
EBV	NULL
-specific	NULL
CTLs	NULL
in	NULL
the	NULL
synovium	NULL
,	NULL
unless	NULL
these	NULL
effectors	NULL
were	NULL
in	NULL
some	NULL
way	NULL
immunocompromised	NULL
in	NULL
situ	NULL
.	NULL

There	NULL
is	NULL
also	NULL
the	NULL
possibility	NULL
that	NULL
EBV	NULL
infection	NULL
in	NULL
the	NULL
synovial	NULL
membrane	NULL
is	NULL
episodic	NULL
and	NULL
dependent	NULL
on	NULL
a	NULL
supply	NULL
of	NULL
virus	NULL
from	NULL
EBV-infected	NULL
B	NULL
cells	NULL
within	NULL
the	NULL
synovium	NULL
.	NULL

We	NULL
can	NULL
now	NULL
predict	NULL
,	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
our	NULL
findings	NULL
,	NULL
that	NULL
antiviral	NULL
bystander	NULL
effects	NULL
could	NULL
also	NULL
be	NULL
potentiated	NULL
by	NULL
crossreactions	NULL
involving	NULL
self	NULL
or	NULL
bacterial	NULL
peptides	NULL
resulting	NULL
from	NULL
molecular	NULL
mimicry	NULL
,	NULL
bystander	NULL
activation	NULL
and/or	NULL
epitope	NULL
spreading	NULL
(	NULL
52	NULL
)	NULL
occurring	NULL
during	NULL
the	NULL
disease	NULL
process	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
a	NULL
possible	NULL
scenario	NULL
is	NULL
that	NULL
MHC	NULL
class	NULL
I-restricted	NULL
crossreactive	NULL
CTLs	NULL
are	NULL
perpetuated	NULL
at	NULL
inflammatory	NULL
sites	NULL
in	NULL
response	NULL
to	NULL
elevated	NULL
levels	NULL
of	NULL
self	NULL
or	NULL
bacterial	NULL
peptides	NULL
presented	NULL
by	NULL
local	NULL
dendritic	NULL
cells	NULL
without	NULL
a	NULL
need	NULL
for	NULL
an	NULL
ongoing	NULL
EBV	NULL
infection	NULL
to	NULL
provide	NULL
continual	NULL
cognitive	NULL
stimulation	NULL
.	NULL

Of	NULL
course	NULL
,	NULL
other	NULL
viruses	NULL
apart	NULL
from	NULL
EBV	NULL
could	NULL
be	NULL
associated	NULL
with	NULL
the	NULL
pathogenesis	NULL
of	NULL
chronic	NULL
rheumatoid	NULL
arthritis	NULL
through	NULL
crossreactions	NULL
,	NULL
in	NULL
a	NULL
fashion	NULL
similar	NULL
to	NULL
the	NULL
implied	NULL
events	NULL
occurring	NULL
in	NULL
autoimmune	NULL
diseases	NULL
such	NULL
as	NULL
multiple	NULL
sclerosis	NULL
,	NULL
in	NULL
which	NULL
patients	NULL
can	NULL
exhibit	NULL
exacerbations	NULL
after	NULL
infections	NULL
with	NULL
different	NULL
viruses	NULL
(	NULL
53	NULL
)	NULL
.	NULL

We	NULL
acknowledge	NULL
Chiron	NULL
Technologies	NULL
for	NULL
their	NULL
kind	NULL
gift	NULL
of	NULL
recombinant	NULL
interleukin	NULL
2	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
funds	NULL
from	NULL
the	NULL
National	NULL
Health	NULL
and	NULL
Medical	NULL
Research	NULL
Council	NULL
of	NULL
Australia	NULL
.	NULL

1	NULL
.	NULL

Miyashita	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Yang	NULL
,	NULL
B.	NULL
,	NULL
Lam	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
Crawford	NULL
,	NULL
D.	NULL
H.	NULL
&	NULL
Thorley-Lawson	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Cell	NULL
80	NULL
,	NULL
593-601	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Karajannis	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Hummel	NULL
,	NULL
M.	NULL
,	NULL
Anagnostopoulos	NULL
,	NULL
I	NULL
.	NULL

&	NULL
Stein	NULL
,	NULL
H.	NULL
(	NULL
1997	NULL
)	NULL
Blood	NULL
89	NULL
,	NULL
2856-2862	NULL
.	NULL

3	NULL
.	NULL

Rowe	NULL
,	NULL
M.	NULL
,	NULL
Rowe	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
Gregory	NULL
,	NULL
C.	NULL
D.	NULL
,	NULL
Young	NULL
,	NULL
L.	NULL
S.	NULL
,	NULL
Farrell	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Rupani	NULL
,	NULL
H.	NULL
&	NULL
Rickinson	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

6	NULL
,	NULL
2743-2751	NULL
.	NULL

4	NULL
.	NULL

Thomas	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

&	NULL
Crawford	NULL
,	NULL
D.	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
Lancet	NULL
1	NULL
,	NULL
1075-1076	NULL
.	NULL

5	NULL
.	NULL

Miyashita	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Yang	NULL
,	NULL
B.	NULL
,	NULL
Babcock	NULL
,	NULL
G.	NULL
J	NULL
.	NULL

&	NULL
Thorley-Lawson	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

71	NULL
,	NULL
4882-4891	NULL
.	NULL

6	NULL
.	NULL

Rickinson	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

&	NULL
Moss	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

15	NULL
,	NULL
405-431	NULL
.	NULL

7	NULL
.	NULL

Callan	NULL
,	NULL
M.	NULL
F.	NULL
C.	NULL
,	NULL
Tan	NULL
,	NULL
L.	NULL
,	NULL
Annels	NULL
,	NULL
N.	NULL
,	NULL
Ogg	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
Wilson	NULL
,	NULL
J.	NULL
D.	NULL
K.	NULL
,	NULL
O'Callaghan	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Steven	NULL
,	NULL
N.	NULL
,	NULL
McMichael	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

&	NULL
Rickinson	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187	NULL
,	NULL
1395-1402	NULL
.	NULL

8	NULL
.	NULL

Silins	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Cross	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Elliott	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Pye	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Burrows	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Burrows	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Moss	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Argaet	NULL
,	NULL
V.	NULL
P.	NULL
&	NULL
Misko	NULL
,	NULL
I.	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184	NULL
,	NULL
1815-1824	NULL
.	NULL

9	NULL
.	NULL

Levitsky	NULL
,	NULL
V.	NULL
,	NULL
de	NULL
Campos-Lima	NULL
,	NULL
P.-O	NULL
.	NULL

,	NULL
Frisan	NULL
,	NULL
T.	NULL
&	NULL
Masucci	NULL
,	NULL
M.	NULL
G.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

161	NULL
,	NULL
594-601	NULL
.	NULL

10	NULL
.	NULL

-	NULL
Sourdive	NULL
,	NULL
D.	NULL
J.	NULL
D.	NULL
,	NULL
Murali-Krishna	NULL
,	NULL
K.	NULL
,	NULL
Altman	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Zajac	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Whitmire	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
Pannetier	NULL
,	NULL
C.	NULL
,	NULL
Kourilsky	NULL
,	NULL
P.	NULL
,	NULL
Evavold	NULL
,	NULL
B.	NULL
,	NULL
Sette	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Ahmed	NULL
,	NULL
R.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

188	NULL
,	NULL
71-82	NULL
.	NULL

11	NULL
.	NULL

Busch	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Pilip	NULL
,	NULL
I	NULL
.	NULL

&	NULL
Pamer	NULL
,	NULL
E.	NULL
G.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

188	NULL
,	NULL
61-70	NULL
.	NULL

12	NULL
.	NULL

Wilson	NULL
,	NULL
R.	NULL
K.	NULL
,	NULL
Lai	NULL
,	NULL
E.	NULL
,	NULL
Concannon	NULL
,	NULL
P.	NULL
,	NULL
Barth	NULL
,	NULL
R.	NULL
K.	NULL
&	NULL
Hood	NULL
,	NULL
L.	NULL
E.	NULL
(	NULL
1988	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

101	NULL
,	NULL
149-172	NULL
.	NULL

13	NULL
.	NULL

Jorgensen	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Esser	NULL
,	NULL
U.	NULL
,	NULL
Fazekas	NULL
de	NULL
St	NULL
Groth	NULL
,	NULL
B.	NULL
,	NULL
Reay	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Davis	NULL
,	NULL
M.	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
355	NULL
,	NULL
224-230	NULL
.	NULL

14	NULL
.	NULL

-	NULL
Garboczi	NULL
,	NULL
D.	NULL
N.	NULL
,	NULL
Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Utz	NULL
,	NULL
U.	NULL
,	NULL
Fan	NULL
,	NULL
Q.	NULL
R.	NULL
,	NULL
Biddison	NULL
,	NULL
W.	NULL
E.	NULL
&	NULL
Wiley	NULL
,	NULL
D.	NULL
C.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
274	NULL
,	NULL
209-219	NULL
.	NULL

15	NULL
.	NULL

Argaet	NULL
,	NULL
V.	NULL
P.	NULL
,	NULL
Schmidt	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
Burrows	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Silins	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Kurilla	NULL
,	NULL
M.	NULL
G.	NULL
,	NULL
Doolan	NULL
,	NULL
D.	NULL
L.	NULL
,	NULL
Suhrbier	NULL
,	NULL
A.	NULL
,	NULL
Moss	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Kieff	NULL
,	NULL
E.	NULL
,	NULL
Sculley	NULL
,	NULL
T.	NULL
B	NULL
.	NULL

&	NULL
Misko	NULL
,	NULL
I.	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180	NULL
,	NULL
2335-2340	NULL
.	NULL

16	NULL
.	NULL

Silins	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Cross	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Elliott	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Pye	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Burrows	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Moss	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

&	NULL
Misko	NULL
,	NULL
I.	NULL
S.	NULL
(	NULL
1997	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

9	NULL
,	NULL
1745-1755	NULL
.	NULL

17	NULL
.	NULL

Tallquist	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
Yun	NULL
,	NULL
T.	NULL
J	NULL
.	NULL

&	NULL
Pease	NULL
,	NULL
L.	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184	NULL
,	NULL
1017-1026	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96	NULL
(	NULL
1999	NULL
)	NULL
Evavold	NULL
,	NULL
B.	NULL
D.	NULL
,	NULL
Sloan-Lancaster	NULL
,	NULL
J.	NULL
,	NULL
Wilson	NULL
,	NULL
K.	NULL
J.	NULL
,	NULL
Rothbard	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

&	NULL
Allen	NULL
,	NULL
P.	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Immunity	NULL
2	NULL
,	NULL
655-663	NULL
.	NULL

Oldstone	NULL
,	NULL
M.	NULL
B	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Cell	NULL
50	NULL
,	NULL
819-820	NULL
.	NULL

Wucherpfennig	NULL
,	NULL
K.	NULL
W.	NULL
&	NULL
Strominger	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
80	NULL
,	NULL
695-705	NULL
.	NULL

Segal	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
Klinman	NULL
,	NULL
D.	NULL
M.	NULL
&	NULL
Shevach	NULL
,	NULL
E.	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

158	NULL
,	NULL
5087-5090	NULL
.	NULL

Bevan	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1977	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
269	NULL
,	NULL
417-418	NULL
.	NULL

Ashton-Rickardt	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Van	NULL
Kaer	NULL
,	NULL
L.	NULL
,	NULL
Schumacher	NULL
,	NULL
T.	NULL
N.	NULL
M.	NULL
,	NULL
Ploegh	NULL
,	NULL
H.	NULL
L.	NULL
&	NULL
Tonegawa	NULL
,	NULL
S.	NULL
(	NULL
1993	NULL
)	NULL
Cell	NULL
73	NULL
,	NULL
1041-1049	NULL
.	NULL

Hu	NULL
,	NULL
Q.	NULL
,	NULL
Bazemore	NULL
Walker	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
Girao	NULL
,	NULL
C.	NULL
,	NULL
Opferman	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Sun	NULL
,	NULL
J.	NULL
,	NULL
Shabanowitz	NULL
,	NULL
J.	NULL
,	NULL
Hunt	NULL
,	NULL
D.	NULL
F.	NULL
&	NULL
Ashton-Rickardt	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1997	NULL
)	NULL
Immunity	NULL
7	NULL
,	NULL
221-231	NULL
.	NULL

Ohashi	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Ochen	NULL
,	NULL
S.	NULL
,	NULL
Buerki	NULL
,	NULL
K.	NULL
,	NULL
Pircher	NULL
,	NULL
H.	NULL
,	NULL
Ohashi	NULL
,	NULL
C.	NULL
T.	NULL
,	NULL
Odermatt	NULL
,	NULL
B.	NULL
,	NULL
Malissen	NULL
,	NULL
B.	NULL
,	NULL
Zinkernagel	NULL
,	NULL
R.	NULL
M.	NULL
&	NULL
Hengartner	NULL
,	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
65	NULL
,	NULL
305-317	NULL
.	NULL

Oldstone	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
Nerenberg	NULL
,	NULL
M.	NULL
,	NULL
Southern	NULL
,	NULL
P.	NULL
,	NULL
Price	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Lewicki	NULL
,	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
65	NULL
,	NULL
319-331	NULL
.	NULL

Countryman	NULL
,	NULL
J.	NULL
,	NULL
Jenson	NULL
,	NULL
H.	NULL
,	NULL
Seibl	NULL
,	NULL
R.	NULL
,	NULL
Wolf	NULL
,	NULL
H.	NULL
&	NULL
Miller	NULL
,	NULL
G.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

61	NULL
,	NULL
3672-3679	NULL
.	NULL

Prang	NULL
,	NULL
N.	NULL
S.	NULL
,	NULL
Hornef	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Jager	NULL
,	NULL
M.	NULL
,	NULL
Wagner	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Wolf	NULL
,	NULL
H.	NULL
&	NULL
Schwarzmann	NULL
,	NULL
F.	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Blood	NULL
89	NULL
,	NULL
1665-1677	NULL
.	NULL

Bogedain	NULL
,	NULL
C.	NULL
,	NULL
Wolf	NULL
,	NULL
H.	NULL
,	NULL
Modrow	NULL
,	NULL
S.	NULL
,	NULL
Stuber	NULL
,	NULL
G.	NULL
&	NULL
Jilg	NULL
,	NULL
W.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

69	NULL
,	NULL
4872-4879	NULL
.	NULL

Elliott	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Pye	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Schmidt	NULL
,	NULL
C.	NULL
,	NULL
Cross	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Silins	NULL
,	NULL
S.	NULL
L.	NULL
&	NULL
Misko	NULL
,	NULL
I.	NULL
S.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

176	NULL
,	NULL
1068-1072	NULL
.	NULL

DiBrino	NULL
,	NULL
M.	NULL
,	NULL
Parker	NULL
,	NULL
K.	NULL
C.	NULL
,	NULL
Shiloach	NULL
,	NULL
J.	NULL
,	NULL
Turner	NULL
,	NULL
R.	NULL
V.	NULL
,	NULL
Tsuchida	NULL
,	NULL
T.	NULL
,	NULL
Garfield	NULL
,	NULL
M.	NULL
,	NULL
Biddison	NULL
,	NULL
W.	NULL
E.	NULL
&	NULL
Coligan	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

152	NULL
,	NULL
620-631	NULL
.	NULL

Baum	NULL
,	NULL
H.	NULL
,	NULL
Butler	NULL
,	NULL
P.	NULL
,	NULL
Davies	NULL
,	NULL
H.	NULL
,	NULL
Sternberg	NULL
,	NULL
M.	NULL
J.	NULL
E.	NULL
&	NULL
Bur-roughs	NULL
,	NULL
A.	NULL
K.	NULL
(	NULL
1993	NULL
)	NULL
Trends	NULL
Biochem	NULL
.	NULL

Sci	NULL
.	NULL

18	NULL
,	NULL
140-144	NULL
.	NULL

Wucherpfennig	NULL
,	NULL
K.	NULL
W.	NULL
&	NULL
Strominger	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181	NULL
,	NULL
1597-1601	NULL
.	NULL

Schmidt	NULL
,	NULL
C.	NULL
,	NULL
Burrows	NULL
,	NULL
S.	NULL
R.	NULL
,	NULL
Sculley	NULL
,	NULL
T.	NULL
B.	NULL
,	NULL
Moss	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

&	NULL
Misko	NULL
,	NULL
I.	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88	NULL
,	NULL
9478-9482	NULL
.	NULL

Misko	NULL
,	NULL
I.	NULL
S.	NULL
,	NULL
Pope	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
Hutter	NULL
,	NULL
R.	NULL
,	NULL
Sosynski	NULL
,	NULL
T.	NULL
D.	NULL
&	NULL
Kane	NULL
,	NULL
R.	NULL
G.	NULL
(	NULL
1984	NULL
)	NULL
Int	NULL
.	NULL

J	NULL
.	NULL

Cancer	NULL
33	NULL
,	NULL
239-243	NULL
.	NULL

Davies	NULL
,	NULL
T.	NULL
F.	NULL
,	NULL
Martin	NULL
,	NULL
A.	NULL
,	NULL
Concepcion	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Graves	NULL
,	NULL
P.	NULL
,	NULL
Cohen	NULL
,	NULL
L.	NULL
&	NULL
Ben-Nun	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

325	NULL
,	NULL
238-244	NULL
.	NULL

Steinle	NULL
,	NULL
A.	NULL
,	NULL
Reinhardt	NULL
,	NULL
C.	NULL
,	NULL
Jantzer	NULL
,	NULL
P.	NULL
&	NULL
Schendel	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181	NULL
,	NULL
503-513	NULL
.	NULL

Arden	NULL
,	NULL
B.	NULL
,	NULL
Clark	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
Kabelitz	NULL
,	NULL
D.	NULL
&	NULL
Mak	NULL
,	NULL
T.	NULL
W.	NULL
(	NULL
1995	NULL
)	NULL
Immunogenetics	NULL
42	NULL
,	NULL
455-500	NULL
.	NULL

Grossman	NULL
,	NULL
Z	NULL
.	NULL

&	NULL
Paul	NULL
,	NULL
W.	NULL
E.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
89	NULL
,	NULL
10365-10369	NULL
.	NULL

Sloan-Lancaster	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Allen	NULL
,	NULL
P.	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14	NULL
,	NULL
1-27	NULL
.	NULL

Chau	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Bluestone	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

&	NULL
Madrenas	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187	NULL
,	NULL
1699-1709	NULL
.	NULL

Macowiak	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1982	NULL
)	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

307	NULL
,	NULL
83-93	NULL
.	NULL

Duchmann	NULL
,	NULL
R.	NULL
,	NULL
Kaiser	NULL
,	NULL
I.	NULL
,	NULL
Hermann	NULL
,	NULL
E.	NULL
,	NULL
Mayet	NULL
,	NULL
W.	NULL
,	NULL
Ewe	NULL
,	NULL
K.	NULL
&	NULL
Meyer	NULL
Zum	NULL
Buschenfelde	NULL
,	NULL
K.-H.	NULL
(	NULL
1995	NULL
)	NULL
Clin	NULL
.	NULL

Exp	NULL
.	NULL

Immunol	NULL
.	NULL

102	NULL
,	NULL
448-455	NULL
.	NULL

Gutgemann	NULL
,	NULL
I.	NULL
,	NULL
Fahrer	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Altman	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Davis	NULL
,	NULL
M.	NULL
M.	NULL
&	NULL
Chien	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Immunity	NULL
8	NULL
,	NULL
667-673	NULL
.	NULL

Tanchot	NULL
,	NULL
C.	NULL
,	NULL
Lemonnier	NULL
,	NULL
F.	NULL
A.	NULL
,	NULL
Perarnau	NULL
,	NULL
B.	NULL
,	NULL
Freitas	NULL
,	NULL
A	NULL
.	NULL

A	NULL
.	NULL

&	NULL
Rocha	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Science	NULL
276	NULL
,	NULL
2057-2062	NULL
.	NULL

Markiewicz	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Girao	NULL
,	NULL
C.	NULL
,	NULL
Opferman	NULL
,	NULL
J.	NULL
T.	NULL
,	NULL
Sun	NULL
,	NULL
J.	NULL
,	NULL
Hu	NULL
,	NULL
Q.	NULL
,	NULL
Agulnik	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
Bishop	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Thompson	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

&	NULL
Ashton-Rickardt	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1998	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
95	NULL
,	NULL
3065-3070	NULL
.	NULL

Pfeifer	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Wick	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Roberts	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Findlay	NULL
,	NULL
K.	NULL
,	NULL
Normark	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

&	NULL
Harding	NULL
,	NULL
C.	NULL
V.	NULL
(	NULL
1993	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
361	NULL
,	NULL
359-362	NULL
.	NULL

Albert	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Sauter	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Bhardwaj	NULL
,	NULL
N.	NULL
(	NULL
1998	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
392	NULL
,	NULL
86-89	NULL
.	NULL

Scotet	NULL
,	NULL
E.	NULL
,	NULL
David-Ameline	NULL
,	NULL
J.	NULL
,	NULL
Peyrat	NULL
,	NULL
M.-A	NULL
.	NULL

,	NULL
Moreau-Aubry	NULL
,	NULL
A.	NULL
,	NULL
Pinczon	NULL
,	NULL
D.	NULL
,	NULL
Lim	NULL
,	NULL
A.	NULL
,	NULL
Even	NULL
,	NULL
J.	NULL
,	NULL
Semana	NULL
,	NULL
G.	NULL
,	NULL
Berthelot	NULL
,	NULL
J.-M.	NULL
,	NULL
Breathnach	NULL
,	NULL
R.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184	NULL
,	NULL
1791-1800	NULL
.	NULL

Takei	NULL
,	NULL
M.	NULL
,	NULL
Mitamura	NULL
,	NULL
K.	NULL
,	NULL
Fujiwara	NULL
,	NULL
S.	NULL
,	NULL
Horie	NULL
,	NULL
T.	NULL
,	NULL
Ryu	NULL
,	NULL
J.	NULL
,	NULL
Osaka	NULL
,	NULL
S.	NULL
,	NULL
Yoshino	NULL
,	NULL
S.	NULL
&	NULL
Sawada	NULL
,	NULL
S.	NULL
(	NULL
1997	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

9	NULL
,	NULL
739-743	NULL
.	NULL

Mousavi-Jazi	NULL
,	NULL
M.	NULL
,	NULL
Bostrom	NULL
,	NULL
L.	NULL
,	NULL
Lovemark	NULL
,	NULL
C.	NULL
,	NULL
Linde	NULL
,	NULL
A.	NULL
,	NULL
Bryt-ting	NULL
,	NULL
M.	NULL
&	NULL
Sundqvist	NULL
,	NULL
V.	NULL
A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Rheumatol	NULL
.	NULL

25	NULL
,	NULL
623-628	NULL
.	NULL

Miller	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
Vanderlugt	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
Begolka	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Pao	NULL
,	NULL
W.	NULL
,	NULL
Yauch	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
Neville	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
Katz-Levy	NULL
,	NULL
Y.	NULL
,	NULL
Carrizosa	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Kim	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Nat	NULL
.	NULL

Med	NULL
.	NULL

3	NULL
,	NULL
1133-1136	NULL
.	NULL

Anderson	NULL
,	NULL
O.	NULL
,	NULL
Lygner	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
Bergstrom	NULL
,	NULL
T.	NULL
,	NULL
Anderson	NULL
,	NULL
M.	NULL
&	NULL
Vahine	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Neurol	NULL
.	NULL

240	NULL
,	NULL
417-422	NULL
.	NULL

